

**LOCAL ANTIMICROBIAL SUSCEPTIBILITY PATTERN DOCUMENT
(JANUARY-DECEMBER 2025)**

EDITORIAL BOARD

Chairman: Dr. Shukla Das, Director Professor & Head

Chief-Editor: Dr. Nisha Goyal, Associate Professor

Members

Dr. Debamita Banik, Senior Resident

Dr Ananya Varshney, Senior Resident

DEPARTMENT OF MICROBIOLOGY, UCMS & GTB HOSPITAL, DELHI

INDEX

S.NO	TITLE	PAGE NO
1	AST OF PUS PATHOGENS	5
2	AST OF LOWER RESPIRATORY PATHOGENS	12
3	AST OF BODY FLUIDS (EXCEPT CSF AND BLOOD) PATHOGENS	17
4	AST OF BLOOD PATHOGENS	22
5	AST OF URINARY PATHOGENS	30
6	AST OF CSF PATHOGENS	38
7	AST OF ENTERIC PATHOGENS	42
8	AST OF PATHOGENS ISOLATED FROM THE MEDICINE DEPARTMENT	46
9	AST OF PATHOGENS ISOLATED FROM THE SURGERY DEPARTMENT	54
10	AST OF PATHOGENS ISOLATED FROM THE PAEDIATRICS DEPARTMENT	60
11	AST OF PATHOGENS ISOLATED FROM THE ORTHOPAEDICS DEPARTMENT	67
12	AST OF PATHOGENS ISOLATED FROM OPHTHALMOLOGY DEPARTMENT	74
13	AST OF PATHOGENS ISOLATED FROM ENT DEPARTMENT	78
14	AST OF PATHOGENS ISOLATED FROM DERMATOLOGY DEPARTMENT	83
15	AST OF PATHOGENS ISOLATED FROM OBSTETRICS & GYNAECOLOGY DEPARTMENT	87

DISCLAIMER: This document is purely for educational purposes and for internal circulation in UCMS & GTB Hospital, Delhi only. No parts/parts shall fully/partially be copied, plagiarized, imitated, published, or reproduced anyway whatsoever, without prior permission from the Chairman of the Editorial Board

DEPARTMENT OF MICROBIOLOGY, UCMS & GTB HOSPITAL, DELHI

AST	ANTIMICROBIAL SUSCEPTIBILITY PATTERN (AST)
MRSA	Methicillin-resistant <i>Staphylococcus aureus</i>
MSSA	Methicillin-Sensitive <i>Staphylococcus aureus</i>
IR	Intrinsic resistant
NT	Not tested
NBP	No breakpoint available

Colouring Scheme used	
	Susceptibility % > 80%
	Susceptibility % = 60-80%
	Susceptibility % <60%
	Data not available (includes IR, NT, NBP)

SAMPLE WISE ANTIMICROBIAL SUSCEPTIBILITY PATTERN

**ANTIBIOTIC SUSCEPTIBILITY
OF PUS PATHOGENS
(JAN – DEC 2025)**

Antimicrobial susceptibility pattern for Gram-positive bacterial isolates from pus specimens

[% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]

Gram Positive Cocci	Location	Isolates(n)	Cefoxitin%(n)	Cotrimoxazole%(n)	Clindamycin% (n)	Erythromycin%(n)	Linezolid%(n)	Tetracycline%(n)	Gentamicin%(n)	Chloramphenicol%(n)	Ciprofloxacin%(n)	Doxycycline%(n)	Ofloxacin%(n)
<i>Staphylococcus aureus</i>	OPD	653	47 (653)	64 (450)	67 (650)	11 (651)	100 (121)	61 (106)	61 (188)	94 (592)	NT	99 (328)	12 (95)
	IPD	362	44 (362)	54 (248)	63 (360)	14 (362)	100 (74)	63 (68)	55 (87)	95 (328)	23 (35)	99 (168)	23 (35)
	ICU	17	71 (17)	91 (11)	71 (17)	38 (16)	NT	NT	80 (5)	100 (15)	NT	100 (11)	0 (2)
<i>MRSA</i>	OPD	344	0 (344)	59 (246)	58 (344)	8 (344)	100 (74)	58 (62)	43 (90)	94 (308)	NT	99 (163)	2 (57)
	IPD	202	0 (202)	55 (132)	57 (202)	8 (202)	100 (39)	58 (36)	47 (49)	93 (185)	0 (1)	99 (89)	17 (24)
	ICU	5	0 (5)	100 (3)	20 (5)	0 (4)	NT	NT	100 (1)	100 (4)	NT	100 (4)	NT
<i>MSSA</i>	OPD	309	100 (309)	71 (204)	76 (306)	14 (307)	100 (47)	66 (44)	77 (98)	95 (284)	NT	100 (165)	26 (38)
	IPD	160	100 (160)	54 (116)	70 (158)	20 (160)	100 (35)	69 (32)	66 (38)	97 (143)	24 (34)	100 (79)	36 (11)
	ICU	12	100 (12)	88 (8)	92 (12)	50 (12)	NT	NT	75 (4)	100 (11)	NT	100 (7)	0 (2)

Gram Positive Cocci	Location	Isolates(n)	Cefoxitin% (n)	Cotrimoxazole%(n)	Clindamycin%(n)	Erythromycin%(n)	Linezolid%(n)	Vancomycin %(n)	Tetracycline%(n)	High level Gentamicin%(n)	Chloramphenicol%(n)	Doxycycline%(n)	Teicoplanin%(n)
<i>CONS</i>	OPD	12	25 (12)	30 (10)	33 (12)	17 (12)	100 (11)	NT	63 (8)	NBP	80 (10)	NT	NT
	IPD	10	20 (10)	33 (9)	20 (10)	0 (10)	100 (10)	NT	0 (2)	NBP	63 (8)	NT	NT
<i>Enterococcus faecalis</i>	OPD	16	IR	IR	IR	27 (11)	100 (2)	100 (16)	NT	44 (16)	80 (10)	100 (3)	100 (11)
	IPD	21	IR	IR	IR	0 (18)	100 (6)	100 (19)	0 (2)	43 (21)	73 (15)	100 (1)	75 (12)
	ICU	1	IR	IR	IR	0 (1)	NT	100 (1)	NT	100 (1)	NT	NT	0 (1)
<i>Enterococcus faecium</i>	OPD	11	IR	IR	IR	11 (9)	100 (2)	100 (10)	NT	100 (1)	86 (7)	100 (1)	100 (10)
	IPD	24	IR	IR	IR	0 (15)	100 (8)	100 (13)	0 (1)	78 (23)	94 (16)	100 (2)	82 (17)
<i>Streptococcus pyogenes</i>	OPD	2	NBP	NBP	NT	100 (1)	100 (2)	100 (1)	0 (2)	NBP	100 (1)	NT	NT
	IPD	1	NBP	NBP	100 (1)	100 (1)	100 (1)	100 (1)	NT	NBP	NT	NT	NT

Antimicrobial susceptibility pattern for Gram-negative bacterial isolates from pus specimens

[% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]


Gram-Negative Bacilli	Location	Isolates (n)	Ceftriaxone%(n)	Cefotaxime%(n)	Gentamicin%(n)	Ciprofloxacin%(n)	Piperacillin-tazobactam%(n)	Amikacin%(n)	Imipenem%(n)	Meropenem%(n)	Ceftazidime %(n)	Cotrimoxazole %(n)	Amoxycillin-Clavulanic acid%(n)	Ampicillin-sulbactam%(n)	Minocycline%(n)	Cefepime%(n)	Ofloxacin%(n)	Colistin%(n)
<i>Escherichia coli</i>	OPD	110	25 (73)	20 (5)	60 (15)	18 (78)	30 (69)	49 (96)	68 (65)	0 (2)	15 (66)	50 (2)	16 (69)	60 (5)	100 (2)	22 (27)	30 (27)	NT
	IPD	178	11 (118)	5 (19)	48 (23)	8 (136)	21 (111)	54 (156)	55 (107)	55 (11)	11 (76)	60 (5)	16 (95)	44 (9)	100 (2)	7 (27)	12 (25)	100 (5)
<i>Klebsiella pneumoniae</i>	OPD	113	28 (67)	18 (11)	60 (10)	19 (81)	22 (68)	45 (103)	60 (72)	0 (1)	33 (84)	NT	25 (60)	33 (3)	NT	43 (28)	43 (28)	100 (8)
	IPD	176	18 (126)	18 (17)	56 (9)	13 (147)	11 (105)	43 (168)	49 (123)	40 (10)	17 (130)	NT	12 (98)	0 (4)	NT	21 (19)	21 (19)	100 (20)
	ICU	9	20 (5)	0 (1)	NT	25 (4)	0 (4)	22 (9)	50 (4)	NT	14 (7)	NT	20 (5)	NT	NT	0 (2)	0 (2)	100 (1)
<i>Klebsiella oxytoca</i>	OPD	15	25 (12)	50 (2)	100 (1)	29 (14)	23 (15)	40 (15)	50 (14)	NT	43 (7)	NT	25 (4)	NT	NT	0 (1)	0 (1)	100 (1)
	IPD	25	12 (17)	0 (2)	0 (3)	6 (16)	33 (12)	27 (21)	64 (14)	0 (1)	13 (15)	NT	12 (17)	NT	NT	14 (7)	29 (7)	100 (1)
<i>Acinetobacter baumannii</i>	OPD	54	9 (35)	14 (7)	21 (28)	15 (40)	24 (25)	11 (27)	25 (28)	25 (4)	0 (23)	33 (3)	IR	12 (26)	0 (3)	0 (8)	NT	100 (3)
	IPD	215	5 (151)	6 (17)	10 (118)	7 (170)	5 (119)	5 (113)	6 (128)	0 (16)	4 (82)	0 (11)	IR	6 (90)	39 (13)	0 (33)	NT	100 (22)
	ICU	25	0 (16)	0 (3)	10 (21)	0 (17)	0 (15)	0 (10)	0 (20)	0 (1)	0 (8)	0 (1)	IR	0 (6)	25 (4)	NT	NT	NT

Gram Negative Bacilli	Location	Isolates (n)	Ceftriaxone%(n)	Cefotaxime%(n)	Gentamicin%(n)	Ciprofloxacin%(n)	Piperacillin-tazobactam%(n)	Amikacin%(n)	Imipenem%(n)	Meropenem%(n)	Ceftazidime %(n)	Cotrimoxazole %(n)	Ampicillin-sulbactam%(n)	Minocycline%(n)	Cefepime%(n)	Ofloxacin%(n)	Colistin%(n)
<i>Enterobacter spp.</i>	OPD	278	20 (207)	39 (13)	43 (54)	21 (215)	31 (172)	49 (228)	58 (182)	50 (2)	23 (212)	29 (7)	IR	100 (2)	34 (56)	30 (54)	100 (13)
	IPD	416	10 (296)	19 (64)	48 (65)	11 (30)	23 (228)	41 (354)	45 (263)	70 (20)	11 (312)	18 (11)	IR	100 (2)	13 (48)	22 (45)	100 (29)
	ICU	16	7 (15)	NT	17 (6)	0 (15)	40 (10)	40 (10)	46 (13)	NT	11 (9)	NT	IR	NT	0 (1)	0 (1)	100 (1)
<i>Proteus vulgaris</i>	OPD	21	60 (20)	100 (1)	40 (15)	44 (16)	73 (15)	80 (5)	60 (10)	NT	33 (3)	NT	60 (5)	IR	67 (3)	50 (2)	IR
	IPD	18	53 (15)	0 (2)	50 (14)	40 (15)	67 (12)	25 (4)	56 (9)	0 (1)	67 (3)	0 (1)	67 (3)	IR	0 (2)	0 (2)	IR
	ICU	2	100 (2)	NT	100 (2)	50 (2)	100 (2)	NT	NT	NT	NT	NT	NT	IR	NT	NT	IR
<i>Proteus mirabilis</i>	OPD	61	56 (50)	33 (6)	43 (35)	19 (42)	83 (25)	44 (27)	NT	100 (1)	53 (17)	0 (2)	57 (21)	IR	79 (14)	57 (14)	IR
	IPD	55	30 (37)	47 (15)	25 (40)	13 (40)	58 (31)	50 (14)	NT	80 (5)	56 (16)	0 (2)	46 (11)	IR	67 (6)	83 (6)	IR


Gram-Negative Bacilli	Location	Isolates(n)	Ceftriaxone%(n)	Cefotaxime%(n)	Gentamicin%(n)	Ciprofloxacin%(n)	Piperacillin-tazobactam%(n)	Amikacin%(n)	Tobramycin%(n)	Aztreonam%(n)	Imipenem%(n)	Meropenem%(n)	Ceftazidime %(n)	Cefepime% (n)	Ofloxacin%(n)	Minocycline%(n)
<i>Citrobacter koseri</i>	OPD	19	41 (17)	0 (2)	67 (9)	25 (12)	50 (14)	70 (10)	NT	NT	71 (14)	NT	33 (6)	50 (2)	50 (2)	100 (1)
	IPD	46	20 (36)	0 (8)	59 (17)	18 (39)	27 (34)	50 (30)	NT	NT	60 (32)	50 (4)	17 (18)	100 (1)	100 (1)	100 (2)
	ICU	1	0 (1)	NT	NT	0 (1)	0 (1)	100 (1)	NT	NT	100 (1)	NT	0 (1)	NT	NT	NT
<i>Citrobacter freundii</i>	OPD	23	47 (15)	25 (8)	50 (8)	47 (19)	53 (17)	31 (16)	NT	NT	53 (15)	50 (2)	25 (8)	0 (1)	0 (1)	NT
	IPD	27	31 (16)	22 (9)	54 (13)	29 (17)	25 (16)	47 (15)	NT	NT	73 (15)	0 (1)	42 (12)	25 (4)	75 (4)	100 (1)
<i>Citrobacter spp.</i>	OPD	2	0 (2)	NT	NT	0 (2)	0 (2)	0 (2)	NT	NT	0 (1)	NT	NT	NT	NT	NT
	IPD	2	50 (2)	NT	NT	0 (2)	100 (2)	100 (2)	NT	NT	100 (2)	NT	50 (2)	NT	NT	NT
	ICU	19	41 (17)	0 (2)	67 (9)	25 (12)	50 (14)	70 (10)	NT	NT	71 (14)	NT	33 (6)	NT	NT	NT
<i>Pseudomonas aeruginosa</i>	OPD	170	IR	IR	NBP	83 (52)	87 (112)	NBP	86 (167)	98 (120)	97 (88)	64 (14)	92 (167)	NT	NT	IR
	IPD	142	IR	IR	NBP	64 (36)	71 (95)	NBP	69 (138)	72 (66)	81 (72)	70 (30)	77 (139)	NT	NT	IR
	ICU	5	IR	IR	NBP	NT	50 (4)	NBP	80 (5)	80 (5)	100 (4)	NT	80 (5)	NT	NT	IR

ANTIBIOTIC SUSCEPTIBILITY OF PUS PATHOGENS JAN – DEC 2025


Distribution of Bacterial Isolates from Pus Specimen



AST pattern of *Staphylococcus aureus* Isolates from Pus Specimen



AST pattern of *Enterobacter spp.* isolates from Pus specimen



**ANTIBIOTIC SUSCEPTIBILITY
OF LOWER RESPIRATORY
TRACT PATHOGENS
(JAN – DEC 2025)**

Antimicrobial susceptibility pattern for Gram-positive bacterial isolates from Lower respiratory tract specimens

[% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]

Gram Positive Cocci	Location	Isolates(n)	Cefoxitin%(n)	Cotrimoxazole%(n)	Clindamycin%(n)	Erythromycin%(n)	Linezolid%(n)	Tetracycline%(n)	Chloramphenicol%(n)	Gentamicin%(n)	Ofloxacin%(n)	Doxycycline%(n)	High level Gentamicin%(n)	Vancomycin%(n)	Teicoplanin%(n)
<i>Staphylococcus aureus</i>	OPD	3	100 (3)	100 (2)	67 (3)	33 (3)	100 (2)	100 (1)	50 (2)	NT	NT	NT	NBP	NT	NT
	IPD	4	50 (4)	100 (2)	0 (4)	0 (4)	100 (1)	NT	100 (3)	0 (1)	100 (1)	100 (1)	NBP	NT	NT
	ICU	1	0 (1)	NT	0 (1)	0 (1)	NT	NT	100 (1)	100 (1)	NT	NT	NBP	NT	NT
<i>MRSA</i>	IPD	2	0 (2)	100 (1)	0 (2)	0 (2)	100 (1)	NT	100 (1)	NT	NT	NT	NBP	NT	NT
	ICU	1	0 (1)	NT	0 (1)	0 (1)	NT	NT	100 (1)	100 (1)	NT	NT	NBP	NT	NT
<i>MSSA</i>	OPD	3	100 (3)	100 (2)	67 (3)	33 (3)	100 (2)	100 (1)	50 (2)	NT	NT	NT	NBP	NT	NT
	IPD	2	100 (2)	100 (1)	0 (2)	0 (2)	NT	NT	100 (2)	0 (1)	100 (1)	100 (1)	NBP	NT	NT
<i>Enterococcus faecium</i>	IPD	2	IR	IR	IR	0 (1)	100 (1)	NBP	NT	IR	NBP	NT	100 (2)	100 (1)	100 (2)




Antimicrobial susceptibility pattern for Gram-negative bacterial isolates from Lower respiratory tract specimens

[% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]

Gram-Negative Bacilli	Location	Isolates (n)	Ceftriaxone%(n)	Gentamicin%(n)	Ciprofloxacin%(n)	Piperacillin-tazobactam%(n)	Amikacin%(n)	Imipenem%(n)	Ceftazidime%(n)	Ampicillin sulbactam%(n)	Amoxicillin-clavulanic acid%(n)	Minocycline%(n)	Cefepime%(n)	Cefotaxime%(n)	Meropenem%(n)	Ofloxacin%(n)	Colistin%(n)
<i>Klebsiella pneumoniae</i>	OPD	67	70 (66)	100 (4)	62 (55)	59 (51)	78 (63)	94 (47)	47 (17)	NT	55 (56)	NT	67 (9)	0 (1)	NT	100 (5)	NT
	IPD	63	41 (59)	75 (4)	25 (52)	37 (43)	58 (57)	85 (39)	13 (24)	NT	31 (48)	NT	64 (36)	0 (1)	0 (1)	60 (5)	100 (2)
	ICU	32	4 (23)	0 (4)	10 (21)	6 (17)	29 (28)	40 (20)	4 (23)	NT	4 (24)	NT	0 (9)	0 (1)	NT	0 (7)	100 (4)
<i>Klebsiella oxytoca</i>	OPD	3	50 (2)	100 (1)	50 (2)	0 (1)	50 (2)	100 (1)	NT	NT	67 (3)	NT	100 (1)	100 (1)	100 (1)	NT	NT
	IPD	3	67 (3)	0 (1)	0 (1)	0 (1)	33 (3)	NT	0 (1)	NT	50 (2)	NT	100 (2)	0 (1)	NT	100 (2)	NT
<i>Acinetobacter baumannii</i>	OPD	1	0 (1)	0 (1)	NT	NT	NT	NT	NT	0 (1)	IR	NT	0 (1)	NT	NT	NBP	NT
	IPD	26	0 (21)	7 (14)	4 (23)	0 (13)	12 (17)	0 (11)	7 (14)	7 (14)	IR	67 (3)	0 (2)	0 (2)	0 (3)	NBP	NT
	ICU	113	0 (74)	3 (80)	1 (84)	0 (76)	5 (43)	0 (74)	14 (22)	0 (39)	IR	13 (8)	11 (8)	0 (18)	0 (12)	NBP	NT
<i>Enterobacter spp.</i>	OPD	63	73 (56)	50 (2)	67 (55)	60 (47)	70 (60)	94 (46)	65 (17)	IR	NT	NT	71 (4)	50 (4)	100 (1)	60 (5)	100 (1)
	IPD	80	35 (69)	88 (8)	31 (52)	38 (40)	43 (74)	65 (34)	23 (26)	IR	NT	NT	38 (21)	14 (7)	100 (1)	46 (13)	100 (5)
	ICU	39	0 (26)	0 (5)	3 (29)	4 (25)	27 (34)	42 (26)	4 (26)	IR	NT	NT	0 (8)	0 (2)	NT	13 (8)	100 (3)

Gram-Negative Bacilli	Location	Isolates (n)	Ceftriaxone%(n)	Gentamicin%(n)	Ciprofloxacin%(n)	Piperacillin-tazobactam%(n)	Amikacin%(n)	Tobramycin%(n)	Imipenem%(n)	Ceftazidime%(n)	Aztreonam%(n)	Amoxicillin-clavulanic acid%(n)	Cefepime%(n)	Meropenem%(n)	Ofloxacin%(n)	Colistin%(n)
<i>Citrobacter koseri</i>	OPD	1	0 (1)	NT	0 (1)	0 (1)	100 (1)	NT	100 (1)	NT	NT	IR	NT	NT	NT	NT
	IPD	1	0 (1)	0 (1)	0 (1)	0 (1)	NT	NT	0 (1)	NT	NT	IR	NT	NT	NT	NT
	ICU	3	0 (3)	100 (3)	0 (2)	0 (2)	NT	NT	0 (2)	0 (1)	NT	IR	NT	NT	NT	NT
<i>Citrobacter freundii</i>	IPD	1	0 (1)	NT	0 (1)	0 (1)	0 (1)	NT	100 (1)	NT	NT	IR	NT	NT	NT	NT
	ICU	1	0 (1)	NT	NT	0 (1)	0 (1)	NT	0 (1)	NT	NT	IR	NT	NT	NT	NT
<i>Escherichia coli</i>	OPD	1	NT	NT	0 (1)	NT	0 (1)	NT	NT	0 (1)	NT	100 (1)	NT	NT	NT	NT
	IPD	3	0 (1)	NT	0 (1)	0 (1)	0 (3)	NT	0 (1)	0 (3)	NT	0 (2)	0 (2)	NT	100 (2)	NT
	ICU	2	NT	NT	NT	NT	0 (2)	NT	NT	0 (2)	NT	NT	0 (2)	NT	0 (2)	NT
<i>Pseudomonas aeruginosa</i>	IPD	2	IR	NBP	NT	0 (2)	NT	100 (2)	50 (2)	100 (2)	0 (1)	IR	NT	NT	NT	NT
	ICU	11	IR	NBP	100 (1)	50 (10)	100 (1)	60 (10)	63 (8)	60 (10)	63 (8)	IR	25 (4)	25 (4)	25 (4)	100 (3)

ANTIBIOTIC SUSCEPTIBILITY OF LOWER RESPIRATORY TRACT PATHOGENS JAN – DEC 2025



**ANTIBIOTIC SUSCEPTIBILITY OF
BODY FLUIDS (EXCEPT CSF AND
BLOOD) PATHOGENS
(JAN – DEC 2025)**

Antimicrobial susceptibility pattern for Gram-positive bacterial isolates from body fluid specimens (except CSF and blood)
 [% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]

Gram Positive Cocci	Location	Isolates(n)	Cefoxitin%(n)	Cotrimoxazole%(n)	Clindamycin%(n)	Erythromycin%(n)	Vancomycin%(n)	Tetracycline%(n)	High Level Gentamicin%(n)	Chloramphenicol%(n)	Gentamicin%(n)	Ofloxacin%(n)	Doxycycline%(n)	Penicillin g%(n)	Teicoplanin%(n)
<i>Staphylococcus aureus</i>	OPD	9	44 (9)	71 (7)	67 (9)	33 (9)	NT	100 (2)	NBP	100 (9)	50 (2)	0 (1)	100 (9)	NT	NT
	IPD	35	54 (35)	42 (24)	60 (35)	17 (35)	NT	50 (4)	NBP	88 (33)	67 (12)	67 (3)	100 (17)	NT	NT
<i>MRSA</i>	OPD	4	0 (4)	67 (3)	50 (4)	0 (4)	NT	100 (1)	NBP	100 (4)	0 (1)	0 (1)	100 (2)	NT	NT
	IPD	15	0 (15)	10 (10)	27 (15)	0 (15)	NT	0 (1)	NBP	77 (13)	0 (4)	0 (1)	100 (7)	NT	NT
<i>MSSA</i>	OPD	5	100 (5)	100 (3)	100 (4)	75 (4)	NT	100 (1)	NBP	100 (4)	100 (1)	NT	100 (1)	NT	NT
	IPD	20	100 (20)	62 (13)	90 (19)	32 (19)	NT	67 (3)	NBP	95 (19)	100 (8)	100 (2)	100 (9)	NT	NT
<i>Enterococcus faecalis</i>	OPD	2	IR	IR	IR	50 (2)	100 (2)	NT	100 (2)	100 (2)	IR	NBP	100 (1)	100 (1)	100 (2)
	IPD	2	IR	IR	IR	0 (1)	100 (2)	NT	100 (2)	100 (1)	IR	NBP	NT	100 (1)	NT
<i>Enterococcus faecium</i>	OPD	2	IR	IR	IR	0 (1)	100 (2)	NT	50 (2)	100 (1)	IR	NBP	NT	NT	100 (2)
	IPD	12	IR	IR	IR	0 (5)	100 (5)	50 (2)	67 (12)	100 (9)	IR	NBP	10 (2)	100 (2)	89 (9)




Antimicrobial susceptibility pattern for Gram-negative bacterial isolates from body fluid specimens (except CSF and blood)

[% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]

Gram-Negative Bacilli	Location	Isolates(n)	Ceftriaxone%(n)	Gentamicin%(n)	Ciprofloxacin%(n)	Piperacillin-tazobactam%(n)	Amikacin%(n)	Imipenem%(n)	Ceftazidime%(n)	Cefotaxime%(n)	Cefepime%(n)	Ofloxacin%(n)	Aztreonam%(n)	Tobramycin%(n)	Colistin%(n)
<i>Escherichia coli</i>	OPD	6	0 (3)	100 (1)	0 (6)	40 (5)	40 (5)	100 (3)	0 (4)	NT	NT	NT	NT	NT	NT
	IPD	48	25 (36)	60 (5)	17 (41)	23 (35)	63 (14)	66 (35)	5 (26)	50 (2)	0 (2)	0 (2)	NT	NT	100 (1)
<i>Klebsiella pneumoniae</i>	OPD	2	NT	NT	NT	NT	0 (2)	NT	0 (2)	NT	0 (2)	50 (2)	NT	NT	NT
	IPD	44	26 (39)	50 (2)	17 (42)	34 (66)	68 (41)	69 (39)	18 (34)	0 (2)	0 (1)	100 (1)	NT	NT	100 (1)
	ICU	1	0 (1)	0 (1)	NT	NT	NT	NT	0 (1)	0 (1)	NT	NT	NT	NT	100 (1)
<i>Klebsiella oxytoca</i>	IPD	1	0 (1)	NT	0 (1)	NT	100 (1)	100 (1)	0 (1)	NT	NT	NT	NT	NT	NT
<i>Acinetobacter baumannii</i>	OPD	1	NT	100 (1)	100 (1)	100 (1)	NT	100 (1)	NT	NT	NT	NT	IR	NT	NT
	IPD	18	0 (14)	40 (5)	31 (13)	17 (6)	36 (14)	25 (4)	17 (6)	NT	20 (5)	NT	IR	NT	NT
	ICU	1	NT	0 (1)	0 (1)	0 (1)	NT	0 (1)	NT	NT	NT	NT	IR	NT	NT
<i>Pseudomonas aeruginosa</i>	OPD	1	IR	NBP	100 (1)	NT	NBP	NT	100 (1)	IR	NT	NT	100 (1)	100 (1)	NT
	IPD	4	IR	NBP	50 (2)	100 (4)	NBP	100 (1)	100 (4)	IR	100 (1)	100 (4)	100 (4)	100 (4)	NT

Gram-Negative Bacilli	Location	Isolates(n)	Ceftriaxone%(n)	Gentamicin%(n)	Ciprofloxacin%(n)	Piperacillin-tazobactam%(n)	Amikacin%(n)	Imipenem%(n)	Ceftazidime%(n)	Cefotaxime%(n)	Cefepime%(n)	Ofloxacin%(n)	Colistin%(n)
<i>Citrobacter koseri</i>	OPD	2	100 (1)	NT	100 (1)	100 (1)	100 (2)	100 (1)	100 (2)	100 (1)	NT	NT	NT
	IPD	8	0 (7)	50 (2)	20 (5)	17 (6)	50 (6)	67 (6)	25 (4)	0 (2)	NT	NT	NT
<i>Citrobacter freundii</i>	OPD	1	NT	NT	0 (1)	0 (1)	100 (1)	100 (1)	NT	NT	NT	NT	NT
	IPD	1	NT	NT	0 (1)	100 (1)	NT	100 (1)	NT	100 (1)	NT	NT	NT
<i>Enterobacter spp.</i>	OPD	9	44 (9)	33 (3)	13 (8)	25 (8)	67 (6)	75 (8)	20 (5)	NT	100 (1)	100 (1)	100 (1)
	IPD	88	12 (68)	56 (9)	17 (72)	26 (57)	59 (80)	52 (66)	10 (72)	0 (11)	11 (9)	0 (9)	100 (2)
	ICU	2	0 (2)	NT	0 (2)	0 (1)	0 (2)	0 (2)	0 (2)	NT	NT	NT	NT
<i>Proteus mirabilis</i>	IPD	2	0 (2)	50 (2)	50 (2)	50 (2)	NT	NT	NT	NT	NT	NT	IR
<i>Proteus vulgaris</i>	IPD	1	0 (1)	0 (1)	0 (1)	0 (1)	NT	NT	NT	NT	NT	NT	IR

ANTIBIOTIC SUSCEPTIBILITY OF BODY FLUID (EXCEPT CSF AND BLOOD) PATHOGENS JAN – DEC 2025



ANTIBIOTIC SUSCEPTIBILITY OF BLOOD PATHOGENS (JAN – DEC 2025)

Antimicrobial susceptibility pattern for Gram-positive bacterial isolates from blood specimens

[% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]

Gram Positive Cocci	Location	Isolates (n)	Cefoxitin%(n)	Cotrimoxazole%(n)	Clindamycin%(n)	Erythromycin%(n)	Linezolid%(n)	Tetracycline%(n)	Ciprofloxacin%(n)	Gentamicin%(n)	Vancomycin %(n)	Doxycycline%(n)	Minocycline%(n)
<i>Staphylococcus aureus</i>	OPD	33	76 (33)	63 (19)	70 (33)	30 (30)	100 (28)	100 (2)	73 (33)	91 (33)	100 (3)	100 (16)	100 (1)
	IPD	196	42 (196)	47 (125)	64 (193)	15 (189)	100 (172)	56 (25)	40 (172)	85 (191)	100 (7)	100 (68)	100 (16)
	ICU	58	48 (58)	64 (36)	40 (58)	16 (57)	100 (51)	100 (1)	35 (43)	79 (56)	100 (1)	100 (10)	100 (9)
<i>MRSA</i>	OPD	8	0 (8)	33 (3)	50 (8)	0 (8)	100 (10)	100 (1)	25 (8)	63 (8)	100 (3)	100 (4)	100 (1)
	IPD	113	0 (113)	34 (64)	50 (111)	6 (109)	100 (129)	40 (15)	26 (102)	78 (110)	100 (6)	100 (4)	100 (9)
	ICU	30	0 (30)	38 (16)	23 (30)	0 (29)	100 (34)	100 (1)	11 (19)	70 (30)	100 (1)	100 (2)	100 (5)
<i>MSSA</i>	OPD	25	100 (25)	69 (16)	76 (25)	41 (22)	100 (18)	100 (1)	88 (25)	100 (25)	NT	100 (12)	NT
	IPD	83	100 (83)	61 (61)	83 (82)	28 (80)	100 (43)	80 (10)	61 (70)	95 (81)	100 (1)	100 (24)	100 (7)
	ICU	28	100 (28)	85 (20)	57 (28)	32 (28)	100 (17)	NT	54 (24)	89 (26)	NT	100 (8)	100 (4)

Gram Positive Cocci	Location	Isolates (n)	Erythromycin%(n)	Linezolid%(n)	Vancomycin%(n)	Ciprofloxacin%(n)	High Level Gentamicin%(n)	Teicoplanin%(n)	Ampicillin%(n)	Doxycycline%(n)
<i>Enterococcus faecalis</i>	OPD	1	0 (1)	100 (1)	NT	NT	0 (1)	0 (1)	100 (1)	NT
	IPD	4	0 (1)	100 (2)	100 (1)	0 (1)	50 (4)	100 (2)	NT	NT
	ICU	8	0 (5)	100 (7)	100 (5)	NT	38 (8)	100 (3)	50 (4)	100 (2)
<i>Enterococcus faecium</i>	OPD	1	0 (1)	100 (1)	100 (1)	NT	100 (1)	NT	100 (1)	100 (1)
	IPD	9	0 (3)	100 (8)	100 (5)	33 (3)	33 (9)	60 (5)	50 (2)	100 (1)
	ICU	6	0 (4)	100 (5)	100 (4)	NT	50 (6)	67 (3)	50 (4)	50 (2)
<i>Enterococcus spp.</i>	OPD	3	0 (2)	100 (2)	100 (1)	0 (1)	67 (3)	0 (1)	100 (2)	100 (1)
	IPD	16	NT	100 (12)	100 (7)	25 (4)	44 (16)	70 (10)	50 (2)	100 (1)
	ICU	4	0 (9)	100 (12)	100 (9)	NT	43 (14)	83 (6)	50 (8)	75 (4)

Antimicrobial susceptibility pattern for Gram-negative bacterial isolates from blood specimens




[% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]


Gram-Negative Bacilli	Location	Isolates (n)	Gentamicin%(n)	Amikacin%(n)	Ceftriaxone%(n)	Piperacillin/tazobactam%(n)	Ciprofloxacin%(n)	Imipenem%(n)	Ceftazidime%(n)	Cefotaxime%(n)	Cefepime%(n)	Meropenem%(n)	Amoxicillin Clavulanate%(n)	Colistin%(n)
<i>Acinetobacter baumannii</i>	OPD	17	58 (12)	50 (16)	56 (9)	50 (6)	38 (16)	25 (8)	25 (4)	20 (5)	83 (6)	40 (5)	IR	100 (1)
	IPD	67	32 (31)	39 (67)	31 (39)	36 (33)	34 (64)	50 (26)	24 (33)	9 (11)	36 (25)	6 (16)	IR	100 (2)
	ICU	103	13 (40)	12 (102)	5 (67)	17 (53)	13 (90)	15 (53)	5 (59)	0 (18)	14 (28)	0 (28)	IR	100 (3)
<i>Acinetobacter spp.</i>	IPD	4	NT	25 (4)	25 (4)	50 (4)	0 (1)	50 (4)	25 (4)	NT	NT	NT	IR	NT
	ICU	1	NT	0 (1)	0 (1)	0 (1)	0 (1)	0 (1)	0 (1)	NT	NT	NT	IR	NT
<i>Escherichia coli</i>	OPD	10	100 (7)	80 (10)	71 (4)	33 (3)	43 (7)	100 (2)	33 (3)	100 (3)	100 (3)	100 (6)	67 (3)	100 (1)
	IPD	45	80 (10)	56 (45)	21 (42)	34 (32)	27 (33)	81 (21)	29 (31)	40 (5)	50 (8)	100 (10)	30 (23)	100 (2)
	ICU	13	80 (5)	39 (13)	27 (11)	25 (8)	33 (6)	100 (3)	20 (5)	0 (3)	75 (4)	80 (5)	67 (3)	NT

Gram-Negative Bacilli	Location	Isolates (n)	Ceftriaxone%(n)	Piperacillin/tazobactam%(n)	Ciprofloxacin%(n)	Imipenem%(n)	Ceftazidime%(n)	Amikacin%(n)	Meropenem%(n)	Azithromycin%(n)	Cotrimoxazole%(n)	Chloramphenicol%(n)	Ampicillin%(n)	Cefixime%(n)
<i>Salmonella Typhi</i>	OPD	33	100 (33)	NBP	0 (33)	100 (24)	NBP	IR	NT	100 (33)	96 (25)	97 (33)	97 (31)	0 (15)
	IPD	69	100 (69)	NBP	11 (64)	100 (59)	NBP	IR	100 (9)	93 (69)	92 (60)	97 (64)	94 (51)	0 (35)
	ICU	3	100 (3)	NBP	0 (3)	100 (1)	NBP	IR	NT	100 (3)	100 (3)	100 (3)	100 (3)	0 (1)
<i>Citrobacter freundii</i>	OPD	2	100 (1)	0 (2)	0 (2)	50 (2)	0 (1)	50 (2)	NT	NBP	NT	NT	NT	NT
	IPD	7	60 (5)	29 (7)	43 (7)	83 (6)	50 (6)	71 (7)	NT	NBP	NT	NT	NT	NT
	ICU	3	0 (2)	0 (3)	0 (2)	50 (2)	33 (3)	33 (3)	NT	NBP	NT	NT	NT	NT
<i>Citrobacter koseri</i>	IPD	6	50 (4)	100 (5)	33 (6)	100 (6)	50 (4)	100 (6)	NT	NBP	NT	NT	NT	NT
	ICU	4	25 (4)	50 (2)	25 (4)	67 (3)	0 (3)	25 (4)	NT	NBP	NT	NT	NT	NT

Gram-Negative Bacilli	Location	Isolates (n)	Amikacin%(n)	Ceftriaxone%(n)	Piperacillin/tazobactam %(n)	Ciprofloxacin%(n)	Imipenem%(n)	Aztreonam%(n)	Ceftazidime%(n)	Cefotaxime%(n)	Cefepime%(n)	Amoxicillin- Clavulanate%(n)	Cotrimoxazole%(n)
<i>Klebsiella pneumoniae</i>	OPD	1	100 (1)	100 (1)	NT	100 (1)	NT	NT	NT	100 (1)	100 (1)	NT	NT
	IPD	30	38 (29)	13 (23)	14 (21)	27 (26)	31 (16)	NT	16 (19)	28 (18)	8 (13)	18 (17)	11 (9)
	ICU	40	28 (40)	10 (30)	11 (18)	19 (36)	38 (16)	NT	9 (11)	16 (19)	13 (23)	6 (18)	43 (7)
<i>Enterobacter spp.</i>	OPD	35	69 (35)	68 (28)	57 (14)	33 (33)	79 (19)	NT	62 (13)	75 (8)	79 (14)	NT	NT
	IPD	74	59 (71)	32 (62)	33 (52)	25 (69)	68 (47)	NT	29 (52)	23 (13)	73 (11)	NT	NT
	ICU	86	35 (86)	7 (75)	7 (43)	11 (80)	28 (50)	NT	8 (40)	0 (13)	17 (23)	NT	0 (1)
<i>Pseudomonas aeruginosa</i>	OPD	2	NBP	IR	100 (2)	NT	100 (2)	0 (1)	100 (2)	IR	NT	IR	IR
	IPD	23	NBP	IR	82 (17)	36 (11)	100 (9)	62 (13)	76 (21)	IR	NT	IR	IR
	ICU	19	NBP	IR	100 (15)	60 (5)	83 (6)	79 (14)	88 (17)	IR	NT	IR	IR
<i>Proteus mirabilis</i>	IPD	7	57 (7)	60 (5)	80 (5)	50 (6)	NT	NT	40 (5)	100 (1)	100 (1)	80 (5)	NT

ANTIBIOTIC SUSCEPTIBILITY OF BLOOD PATHOGENS JAN – DEC 2025





- Most *Candida* species isolated from blood specimen from the ICU are susceptible to Fluconazole (77%) and Voriconazole (83%).
- *Candida krusei* is intrinsically resistant to Fluconazole but remains susceptible to Voriconazole.

**ANTIBIOTIC SUSCEPTIBILITY OF
URINARY PATHOGENS
(JAN – DEC 2025)**

Antimicrobial susceptibility pattern for Gram-positive bacterial isolates from urine specimen

[% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]

Gram Positive Cocci	Location	Isolates (n)	Cotrimoxazole% (n)	Cefoxitin%(n)	Tetracycline%(n)	Linezolid%(n)	Gentamicin%(n)	Ciprofloxacin%(n)	Norfloracin%(n)	Nitrofurantoin%(n)
<i>Staphylococcus aureus</i>	OPD	88	57 (7)	55 (88)	86 (35)	100 (63)	68 (75)	37 (19)	49 (61)	97 (77)
	IPD	20	65 (5)	35 (20)	100 (3)	100 (15)	60 (15)	29 (7)	24 (17)	95 (19)
<i>MRSA</i>	OPD	38	25 (4)	0 (38)	79 (14)	100 (26)	50 (34)	0 (8)	32 (22)	100 (31)
	IPD	13	50 (4)	0 (13)	100 (1)	100 (11)	46 (11)	40 (5)	10 (10)	100 (12)
<i>MSSA</i>	OPD	50	100 (3)	100 (50)	91 (21)	100 (37)	83 (41)	64 (11)	59 (39)	96 (46)
	IPD	7	100 (1)	100 (7)	100 (2)	100 (4)	100 (4)	0 (2)	43 (7)	86 (7)
<i>CONS</i>	OPD	2	NT	50 (2)	NT	100 (2)	100 (1)	100 (1)	100 (2)	100 (2)

Gram Positive Cocci	Location	Isolates (n)	Tetracycline%(n)	Linezolid%(n)	Vancomycin%(n)	High level gentamicin%(n)	Teicoplanin%(n)	Ciprofloxacin%(n)	Norfloxacin%(n)	Nitrofurantoin%(n)	Ampicillin%(n)
<i>Enterococcus faecalis</i>	OPD	111	16 (38)	100 (96)	99 (110)	59 (101)	83 (35)	19 (83)	20 (35)	83 (105)	67 (6)
	IPD	61	16 (19)	100 (52)	96 (54)	46 (57)	94 (16)	6 (51)	15 (27)	64 (53)	33 (6)
	ICU	5	50 (2)	100 (3)	100 (5)	20 (5)	100 (2)	50 (4)	0 (2)	60 (5)	NT
<i>Enterococcus spp.</i>	OPD	4	NT	100 (4)	100 (3)	50 (4)	NT	0 (3)	50 (2)	75 (4)	NT
	IPD	2	NT	100 (2)	100 (1)	0 (2)	NT	0 (1)	0 (1)	50 (2)	NT
<i>Enterococcus faecium</i>	OPD	95	33 (24)	100 (87)	100 (89)	78 (90)	98 (43)	19 (65)	26 (19)	88 (85)	62 (13)
	IPD	34	17 (12)	100 (25)	97 (32)	64 (28)	80 (20)	19 (16)	21 (14)	74 (31)	67 (6)
	ICU	3	0 (2)	100 (3)	67 (3)	0 (3)	0 (2)	33 (3)	NT	50 (2)	67 (3)

Antimicrobial susceptibility pattern for Gram-negative bacterial isolates from urine specimens


[% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]

Gram-Negative Bacilli	Location	Isolates (n)	Gentamicin%(n)	Piperacillin-tazobactam%(n)	Ciprofloxacin%(n)	Meropenem%(n)	Amikacin%(n)	Ceftiaxone%(n)	Imipenem%(n)	Norfloxacin%(n)	Nitrofurantoin%(n)	Cotrimoxazole%(n)	Ceftazidime%(n)	Amoxicillin Clavulanic acid %(n)	Cefuroxime %(n)	Cefotaxime%(n)	Cefepime%(n)	Cefixime%(n)	Ertapenem%(n)	Doxycycline%(n)	Tetracycline%(n)	Colistin%(n)
<i>Escherichia coli</i>	OPD	526	68 (499)	67 (319)	26 (61)	67 (9)	61 (174)	39 (271)	97 (291)	31 (371)	86 (506)	37 (320)	0 (1)	33 (191)	33 (12)	30 (250)	53 (15)	40 (37)	83 (6)	67 (3)	18 (74)	100 (6)
	IPD	226	65 (202)	56 (156)	20 (25)	64 (14)	50 (64)	16 (135)	95 (126)	24 (189)	74 (219)	33 (159)	NT	21 (62)	0 (8)	14 (92)	0 (8)	40 (5)	40 (5)	75 (4)	17 (57)	100 (5)
	ICU	14	50 (14)	29 (7)	0 (5)	0 (3)	44 (9)	20 (10)	57 (7)	12 (8)	64 (14)	25 (4)	NT	11 (9)	0 (3)	14 (7)	0 (3)	NT	0 (3)	NT	100 (1)	100 (1)
<i>Enterobacter spp.</i>	OPD	627	68 (613)	61 (406)	17 (41)	78 (9)	54 (97)	35 (454)	87 (465)	42 (449)	68 (609)	42 (479)	0 (2)	NT	NT	27 (173)	0 (3)	21 (48)	NT	NT	24 (42)	100 (4)
	IPD	320	57 (313)	37 (225)	11 (18)	75 (4)	42 (43)	19 (234)	57 (236)	29 (226)	54 (312)	27 (252)	0 (1)	NT	NT	14 (78)	0 (2)	17 (6)	NT	NT	24 (53)	100 (7)
	ICU	27	33 (27)	25 (12)	0 (2)	0 (1)	11 (9)	0 (14)	33 (12)	4 (23)	48 (27)	14 (14)	NT	NT	NT	0 (13)	NT	100 (1)	NT	NT	0 (5)	NT
<i>Klebsiella pneumoniae</i>	OPD	179	78 (174)	67 (128)	57 (7)	50 (2)	68 (22)	64 (132)	88 (146)	79 (84)	27 (176)	61 (145)	0 (1)	45 (52)	NT	62 (45)	0 (1)	57 (7)	NT	NT	46 (13)	100 (4)
	IPD	87	55 (82)	47 (68)	17 (6)	NT	40 (15)	24 (62)	72 (67)	38 (55)	19 (84)	24 (66)	NT	6 (17)	NT	13 (23)	NT	50 (2)	NT	NT	25 (12)	100 (3)
	ICU	14	18 (11)	25 (8)	0 (3)	100 (1)	0 (5)	0 (8)	50 (6)	14 (7)	14 (14)	29 (7)	0 (1)	0 (4)	NT	0 (5)	NT	0 (1)	NT	NT	NT	100 (1)


Gram-Negative Bacilli	Location	Isolates (n)	Gentamicin%(n)	Tetracycline%(n)	Piperacillin-tazobactam%(n)	Ciprofloxacin%(n)	Meropenem%(n)	Amikacin%(n)	Ceftriaxone%(n)	Nitrofurantoin%(n)	Cefotaxime%(n)	Amoxicillin Clavulanic acid %(n)	Colistin%(n)
<i>Klebsiella oxytoca</i>	OPD	59	71 (59)	25 (4)	54 (41)	25 (4)	NT	43 (7)	52 (52)	50 (58)	12 (8)	43 (14)	100 (1)
	IPD	24	70 (23)	50 (2)	47 (17)	0 (1)	100 (1)	100 (1)	35 (17)	33 (24)	17 (6)	67 (3)	100 (2)
	ICU	5	40 (5)	NT	0 (2)	NT	NT	0 (1)	0 (3)	0 (4)	0 (3)	33 (3)	NT
<i>Citrobacter koseri</i>	OPD	66	67 (58)	33 (6)	76 (38)	33 (3)	NT	71 (14)	39 (44)	85 (62)	41 (22)	NT	NT
	IPD	33	69 (29)	33 (3)	62 (21)	NT	0 (2)	60 (5)	14 (21)	56 (32)	22 (9)	NT	NT
	ICU	1	0 (1)	NT	100 (1)	NT	NT	NT	NT	0 (1)	0 (1)	NT	NT
<i>Citrobacter freundii</i>	OPD	19	89 (18)	50 (2)	74 (15)	0 (1)	100 (1)	0 (2)	82 (11)	37 (19)	25 (8)	IR	NT
	IPD	8	75 (8)	NT	75 (8)	NT	NT	NT	50 (6)	50 (8)	50 (2)	IR	NT
	ICU	1	0 (1)	NT	100 (1)	NT	NT	NT	0 (1)	100 (1)	NT	IR	NT
<i>Citrobacter species</i>	OPD	4	50 (4)	NT	50 (4)	NT	NT	NT	0 (2)	75 (4)	0 (1)	NT	NT
	IPD	4	50 (4)	0 (1)	50 (2)	NT	NT	0 (1)	0 (3)	25 (4)	0 (1)	NT	NT

Gram-Negative Bacilli	Location	Isolates (n)	Gentamicin%(n)	Piperacillin-tazobactam %(n)	Meropenem%(n)	Amikacin %(n)	Ceftriaxone%(n)	Imipenem%(n)	Norfloxacin%(n)	Nitrofurantoin%(n)	Ceftazidime%(n)	Cefotaxime%(n)	Ciprofloxacin%(n)	Cotrimoxazole%(n)	Amoxicillin Clavulanic acid %(n)	Colistin%(n)
<i>Acinetobacter baumannii</i>	OPD	23	70 (23)	67 (15)	NT	50 (2)	17 (6)	75 (20)	0 (6)	0 (8)	0 (3)	12 (8)	33 (3)	50 (6)	IR	NT
	IPD	39	29 (38)	12 (25)	0 (1)	17 (12)	6 (16)	12 (24)	0 (3)	0 (14)	0 (6)	6 (16)	0 (2)	12 (8)	IR	100 (3)
	ICU	6	20 (5)	0 (1)	NT	0 (4)	0 (2)	0 (2)	NT	0 (1)	NT	0 (4)	50 (2)	NT	IR	NT
<i>Proteus mirabilis</i>	OPD	35	66 (35)	100 (24)	100 (10)	67 (6)	76 (25)	NT	78 (23)	NT	NT	56 (9)	0 (2)	54 (26)	27 (11)	IR
	IPD	7	14 (7)	67 (6)	NT	0 (1)	25 (4)	NT	60 (5)	NT	NT	0 (3)	NT	17 (6)	0 (1)	IR
	ICU	2	0 (2)	100 (1)	NT	0 (1)	0 (1)	NT	100 (1)	NT	NT	0 (1)	0 (1)	0 (1)	NT	IR
<i>Proteus vulgaris</i>	OPD	31	65 (29)	88 (26)	NT	0 (1)	54 (22)	NT	48 (27)	NT	NT	71 (7)	NT	29 (24)	25 (4)	IR
	IPD	7	50 (6)	100 (6)	NT	0 (1)	14 (7)	NT	14 (7)	NT	NT	NT	NT	14 (7)	0 (1)	IR
	ICU	1	0 (1)	NT	NT	0 (1)	NT	NT	0 (1)	NT	NT	0 (1)	NT	NT	0 (1)	IR


Gram-Negative Bacilli	Location	Isolates (n)	Gentamicin%(n)	Piperacillin-tazobactam %(n)	Amikacin %(n)	Imipenem%(n)	Norfloxacin%(n)	Ceftazidime%(n)	Ciprofloxacin%(n)	Aztreonam %(n)	Tobramycin%(n)
<i>Pseudomonas aeruginosa</i>	OPD	16	0 (3)	75 (12)	NT	100 (6)	92 (12)	64 (11)	91 (11)	100 (9)	92 (13)
	IPD	12	0 (2)	43 (7)	0 (1)	71 (7)	36 (8)	43 (7)	29 (7)	60 (10)	50 (8)




AST pattern of *Escherichia coli* isolates from Urine specimen



AST pattern of *Staphylococcus aureus* isolates from Urine specimen



AST pattern of *Enterococcus faecalis* isolates from Urine specimen



**ANTIBIOTIC SUSCEPTIBILITY OF
CSF PATHOGENS
(JAN – DEC 2025)**




Gram Positive Cocci	Location	Isolates (n)	Cotrimoxazole%(n)	Cefoxitin%(n)	Vancomycin%(n)	Linezolid%(n)	High level Gentamicin %(n)	Gentamicin %(n)
<i>Staphylococcus aureus</i>	IPD	26	42 (19)	62 (26)	NT	100 (24)	NBP	85 (26)
	ICU	5	75 (4)	100 (5)	NT	100 (5)	NBP	100 (5)
<i>MRSA</i>	IPD	10	38 (8)	0 (10)	NT	100 (9)	NBP	70 (10)
<i>MSSA</i>	IPD	16	46 (11)	100 (16)	NT	100 (15)	NBP	94 (16)
	ICU	5	75 (4)	100 (5)	NT	100 (5)	NBP	100 (5)
<i>CONS</i>	IPD	1	NT	NT	NT	100 (1)	NBP	100 (1)
	ICU	1	NT	NT	NT	100 (1)	NBP	100 (1)
<i>Enterococcus spp.</i>	IPD	1	IR	NT	100 (1)	100 (1)	100 (1)	IR
	ICU	1	IR	NT	NT	100 (1)	0 (1)	IR
<i>Enterococcus faecalis</i>	IPD	9	IR	NT	100 (9)	100 (9)	78 (9)	IR
	ICU	4	IR	NT	100 (3)	100 (4)	50 (4)	IR

Antimicrobial susceptibility pattern for Gram-negative bacterial isolates from CSF specimens

[% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]

Gram-Negative Bacilli	Location	Isolates (n)	Ceftriaxone%(n)	Gentamicin%(n)	Cotrimoxazole%(n)	Piperacillin /Tazobactam%(n)	Amikacin%(n)	Tobramycin%(n)	Ceftazidime%(n)	Aztreonam%(n)	Cefotaxime%(n)	Meropenem%(n)	Colistin%(n)
<i>Acinetobacter baumannii</i>	IPD	25	NT	68 (25)	NT	52 (25)	NT	NT	40 (25)	IR	NT	60 (20)	NT
	ICU	3	NT	0 (3)	NT	0 (3)	NT	NT	0 (3)	IR	NT	0 (3)	NT
<i>Pseudomonas aeruginosa</i>	IPD	1	IR	NBP	IR	100 (1)	NBP	100 (1)	100 (1)	100 (1)	IR	100 (1)	NT
<i>Escherichia coli</i>	IPD	14	11 (9)	80 (10)	50 (8)	31 (13)	100 (2)	NT	13 (8)	NT	10 (10)	100 (10)	NT
	ICU	1	NT	100 (1)	0 (1)	0 (1)	100 (1)	NT	NT	NT	NT	0 (1)	NT
<i>Klebsiella pneumoniae</i>	IPD	6	0 (3)	60 (5)	33 (3)	20 (5)	100 (1)	NT	0 (3)	NT	NT	80 (5)	NT
	ICU	5	0 (5)	100 (5)	NT	40 (5)	67 (3)	NT	0 (1)	NT	NT	75 (5)	NT
<i>Enterobacter spp.</i>	IPD	19	14 (14)	82 (17)	0 (6)	44 (16)	80 (5)	NT	27 (11)	NT	31 (16)	63 (16)	100 (1)
	ICU	5	0 (2)	33 (3)	NT	20 (5)	0 (1)	NT	0 (4)	NT	0 (5)	25 (4)	NT
<i>Klebsiella oxytoca</i>	IPD	1	100 (1)	100 (1)	NT	100 (1)	100 (1)	NT	0 (1)	NT	100 (1)	100 (1)	NT

ANTIBIOTIC SUSCEPTIBILITY OF CSF PATHOGENS JAN – DEC 2025





ANTIBIOTIC SUSCEPTIBILITY OF ENTERIC PATHOGENS (JAN – DEC 2025)

Antimicrobial susceptibility pattern for Gram-negative bacterial isolates from stool specimens

[% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]

Gram Negative Organism	Location	Isolates (n)	Ceftriaxone%(n)	Ciprofloxacin%(n)	Imipenem%(n)	Cotrimoxazole%(n)	Cefotaxime%(n)	Tetracycline %(n)	Ampicillin%(n)	Chloramphenicol%(n)	Cefixime%(n)	Azithromycin%(n)
<i>Salmonella Enteritidis</i>	IPD	1	0 (1)	0 (1)	100 (1)	100 (1)	NT	NT	0 (1)	100 (1)	0 (1)	NT
	OPD	1	100 (1)	0 (1)	100 (1)	100 (1)	NT	NT	100 (1)	NT	NT	NT
<i>Shigella species</i>	IPD	3	33 (3)	67 (3)	100 (1)	50 (2)	0 (1)	NT	0 (2)	50 (2)	NT	0 (2)
	OPD	6	0 (5)	0 (5)	100 (3)	17 (6)	0 (2)	NT	0 (5)	100 (3)	NT	60 (5)
<i>Shigella sonnei</i>	IPD	2	0 (1)	0 (1)	100 (1)	0 (1)	0 (1)	NT	0 (1)	0 (1)	NT	0 (2)
<i>Vibrio cholerae</i>	IPD	1	NT	NT	NT	100 (1)	NT	100 (1)	NT	100 (1)	NT	100 (1)

ANTIBIOTIC SUSCEPTIBILITY OF ENTERIC PATHOGENS JAN – DEC 2025



DEPARTMENT WISE ANTIMICROBIAL SUSCEPTIBILITY PATTERNS

**ANTIBIOTIC SUSCEPTIBILITY OF
PATHOGENS ISOLATED FROM MEDICINE
DEPARTMENT
(JAN – DEC 2025)**

Antimicrobial susceptibility for Gram-positive pathogens from the Medicine department

[% of susceptible (total number of isolates tested for a given antibiotic) = % (n)]

Gram Positive Cocci	Location	Number of isolates	Cefoxitin % (n)	Gentamicin % (n)	Ciprofloxacin % (n)	Cotrimoxazole % (n)	Clindamycin % (n)	Erythromycin % (n)	Linezolid % (n)	Chloramphenicol % (n)	Tetracycline % (n)	Norfloxacin % (n)	Ofloxacin % (n)	Nitrofurantoin % (n)	Doxycycline % (n)	Minocycline % (n)	Vancomycin % (n)
<i>Staphylococcus aureus</i>	OPD	65	64 (65)	68 (47)	58 (24)	68 (28)	73 (48)	13 (46)	100 (35)	96 (22)	94 (18)	39 (13)	0 (11)	93 (14)	100 (14)	100 (1)	100 (1)
	IPD	163	43 (163)	76 (127)	32 (93)	46 (115)	65 (134)	14 (134)	100 (124)	98 (42)	58 (31)	40 (5)	60 (5)	86 (7)	100 (48)	100 (8)	100 (5)
	ICU	13	54 (13)	77 (13)	40 (10)	67 (9)	46 (13)	23 (13)	100 (9)	NT	NT	NT	NT	NT	100 (1)	100 (2)	NT
<i>MRSA</i>	OPD	23	0 (23)	33 (18)	17 (6)	67 (6)	69 (16)	0 (16)	100 (9)	100 (10)	100 (6)	17 (6)	0 (7)	100 (5)	100 (3)	100 (1)	100 (1)
	IPD	92	0 (92)	67 (75)	20 (59)	35 (60)	49 (77)	4 (77)	100 (86)	95 (20)	44 (18)	0 (2)	33 (3)	100 (4)	100 (28)	100 (6)	100 (4)
	ICU	6	0 (6)	67 (6)	0 (4)	33 (3)	17 (6)	0 (6)	100 (6)	NT	NT	NT	NT	NT	100 (1)	NT	NT
<i>MSSA</i>	OPD	42	100 (42)	90 (29)	72 (18)	68 (22)	75 (32)	20 (30)	100 (26)	92 (12)	92 (12)	57 (7)	0 (4)	89 (9)	100 (11)	NT	NT
	IPD	71	100 (71)	90 (52)	53 (34)	53 (55)	86 (58)	27 (58)	100 (36)	100 (22)	77 (13)	67 (3)	100 (2)	67 (3)	100 (20)	100 (2)	100 (1)
	ICU	7	100 (7)	86 (7)	67 (6)	83 (6)	71 (7)	43 (7)	100 (3)	NT	NT	NT	NT	NT	NT	NT	NT

Gram Positive Cocci	Location	Number of isolates	High level gentamicin %(n)	Ciprofloxacin %(n)	Erythromycin %(n)	Linezolid %(n)	Vancomycin %(n)	Chloramphenicol %(n)	Tetracycline %(n)	Teicoplanin %(n)	Ampicillin %(n)	Nitrofurantoin %(n)	Norflaxacin %(n)	Doxycycline %(n)
<i>Enterococcus faecalis</i>	OPD	34	55 (29)	25 (28)	0 (1)	100 (27)	100 (32)	NT	30 (10)	73 (11)	100 (3)	77 (30)	33 (9)	NT
	IPD	25	58 (24)	7 (15)	0 (2)	100 (21)	96 (22)	NT	33 (9)	67 (9)	0 (1)	50 (14)	0 (6)	NT
	ICU	8	25 (8)	67 (3)	0 (3)	100 (6)	100 (8)	NT	50 (2)	100 (4)	50 (4)	75 (4)	0 (1)	100 (2)
<i>Enterococcus faecium</i>	OPD	26	76 (25)	19 (16)	0 (2)	100 (21)	100 (24)	NT	33 (9)	100 (11)	75 (4)	83 (18)	0 (4)	NT
	IPD	30	68 (28)	0 (7)	0 (4)	NT	96 (25)	100 (3)	0 (6)	77 (17)	50 (4)	69 (13)	17 (6)	100 (4)
	ICU	6	0 (6)	50 (2)	0 (3)	NT	75 (4)	100 (1)	0 (1)	20 (5)	50 (4)	50 (2)	NT	100 (1)
<i>Enterococcus spp.</i>	OPD	3	33 (3)	0 (2)	NT	100 (2)	100 (1)	NT	NT	NT	NT	50 (2)	50 (2)	NT
	IPD	2	50 (2)	NT	NT	100 (2)	100 (1)	NT	NT	50 (2)	NT	NT	NT	NT

Gram Positive Cocci	Location	Number of isolates	Clindamycin %(n)	Erythromycin %(n)	Linezolid %(n)	Vancomycin %(n)	Chloramphenicol %(n)	Tetracycline %(n)
<i>Streptococcus pneumoniae</i>	IPD	3	100 (2)	0 (2)	100 (3)	100 (2)	100 (3)	0 (2)
<i>Streptococcus pyogenes</i>	IPD	1	NT	NT	100 (1)	100 (1)	NT	100 (1)


Antimicrobial susceptibility for Gram-negative pathogens from the Medicine department
 [% of susceptible (total number of isolates tested for a given antibiotic)]

Gram-Negative Bacilli	Location	Isolates	Ceftriaxone%(n)	Piperacillin-tazobactam%(n)	Gentamicin%(n)	Ciprofloxacin%(n)	Cotrimoxazole%(n)	Imipenem%(n)	Meropenem%(n)	Amikacin%(n)	Tetracycline%(n)	Ceftazidime%(n)	Cefotaxime %(n)	Ampicillin-Sulbactam%(n)	Ampicillin %(n)	Cefuroxime %(n)	Ertapenem %(n)	Amoxicillin-Clavulanic acid%(n)	Nitrofurantoin %(n)	Norfloxacin %(n)	Ofloxacin %(n)	Cefepime%(n)	Doxycycline%(n)	Cefixime%(n)	Colistin %(n)
<i>Escherichia coli</i>	OPD	154	35 (82)	60 (88)	69 (127)	41 (34)	38 (81)	90 (72)	100 (4)	55 (67)	19 (26)	11 (9)	33 (64)	67 (3)	64 (11)	50 (2)	100 (1)	38 (53)	84 (125)	35 (89)	40 (5)	44 (9)	100 (2)	58 (12)	100 (1)
	IPD	139	11 (95)	35 (106)	56 (78)	24 (46)	31 (62)	87 (69)	88 (17)	51 (72)	15 (34)	21 (33)	14 (44)	50 (2)	0 (3)	0 (3)	0 (2)	6 (52)	65 (76)	9 (70)	40 (5)	9 (11)	100 (1)	NT	100 (3)
	ICU	9	20 (5)	0 (1)	25 (8)	20 (5)	0 (1)	0 (2)	0 (3)	33 (9)	NT	0 (1)	0 (5)	NT	0 (1)	0 (2)	0 (2)	14 (7)	57 (7)	0 (3)	0 (1)	0 (3)	NT	NT	100 (1)
<i>Enterobacter spp.</i>	OPD	254	42 (192)	56 (162)	65 (172)	52 (86)	37 (123)	87 (172)	89 (9)	57 (122)	23 (13)	49 (33)	29 (55)	IR	IR	NT	NT	NT	70 (157)	35 (112)	23 (13)	48 (27)	NT	11 (9)	100 (3)
	IPD	243	26 (184)	31 (156)	57 (120)	21 (118)	21 (73)	58 (140)	44 (18)	53 (142)	31 (26)	13 (93)	8 (48)	IR	IR	NT	NT	NT	52 (83)	26 (65)	26 (19)	36 (33)	NT	50 (2)	100 (10)
	ICU	100	0 (71)	13 (54)	21 (43)	5 (74)	0 (9)	42 (59)	14 (7)	26 (80)	0 (3)	8 (48)	0 (17)	IR	IR	NT	NT	NT	41 (17)	7 (15)	11 (9)	0 (22)	NT	NT	100 (5)
<i>Klebsiella pneumoniae</i>	OPD	126	66 (103)	57 (82)	76 (53)	58 (60)	53 (40)	91 (88)	50 (2)	68 (81)	0 (2)	35 (26)	64 (14)	NT	IR	NT	NT	53 (68)	31 (49)	70 (23)	58 (12)	47 (17)	NT	0 (1)	NT
	IPD	102	36 (88)	36 (77)	50 (32)	28 (71)	25 (20)	72 (68)	13 (8)	55 (78)	38 (8)	18 (38)	22 (18)	NT	IR	0 (4)	0 (1)	27 (63)	39 (18)	38 (16)	60 (5)	35 (17)	NT	NT	100 (5)
	ICU	53	8 (36)	11 (28)	25 (28)	15 (34)	22 (9)	43 (30)	67 (12)	23 (43)	NT	8 (25)	13 (15)	NT	IR	0 (3)	0 (1)	3 (32)	18 (11)	17 (6)	0 (6)	13 (16)	NT	0 (1)	100 (10)
<i>Klebsiella oxytoca</i>	OPD	24	50 (20)	54 (13)	64 (22)	50 (4)	47 (15)	73 (15)	100 (1)	43 (7)	0 (1)	0 (1)	50 (4)	NT	IR	NT	NT	50 (10)	45 (20)	38 (8)	NT	100 (1)	NT	0 (3)	100 (1)
	IPD	19	29 (17)	33 (12)	73 (11)	25 (8)	33 (9)	64 (11)	50 (2)	46 (11)	50 (2)	0 (7)	50 (4)	NT	IR	NT	NT	14 (7)	33 (9)	38 (8)	100 (2)	100 (2)	NT	NT	NT
	ICU	4	0 (2)	0 (3)	33 (3)	NT	0 (3)	0 (3)	NT	0 (1)	NT	0 (1)	0 (2)	NT	IR	NT	NT	0 (2)	0 (3)	0 (3)	NT	NT	NT	NT	NT


Gram-Negative Bacilli	Location	Isolates	Ceftriaxone%(n)	Cefotaxime %(n)	Piperacillin Tazobactam %(n)	Gentamicin %(n)	Ciprofloxacin %(n)	Imipenem %(n)	Meropenem %(n)	Tobramycin %(n)	Amikacin %(n)	Aztreonam %(n)	Ceftazidime %(n)	Cotrimoxazole %(n)	Norfloxacin %(n)	Nitrofurantoin %(n)	Netilmicin %(n)	Amoxicillin- Clavulanic acid %(n)	Ampicillin- Sulbactam %(n)	Minocycline %(n)	Cefepime %(n)	Colistin %(n)
<i>Pseudomonas aeruginosa</i>	OPD	8	IR	IR	100 (6)	NBP	100 (3)	100 (3)	NT	86 (7)	NT	83 (6)	88 (8)	IR	100 (3)	IR	100 (2)	IR	IR	IR	100 (1)	NT
	IPD	28	IR	IR	74 (19)	NBP	31 (13)	81 (16)	71 (7)	57 (23)	50 (8)	67 (15)	78 (23)	IR	33 (3)	IR	83 (6)	IR	IR	IR	NT	100 (1)
	ICU	23	IR	IR	70 (20)	NBP	60 (5)	73 (15)	40 (5)	50 (18)	33 (3)	56 (16)	70 (20)	IR	NT	IR	50 (6)	IR	IR	IR	0 (3)	100 (3)
<i>Citrobacter koseri</i>	OPD	21	40 (15)	17 (6)	64 (14)	57 (14)	40 (5)	86 (14)	NT	NT	80 (10)	NT	100 (1)	18 (11)	36 (11)	80 (15)	NT	NT	NT	NT	NT	NT
	IPD	9	0 (7)	100 (1)	60 (5)	67 (3)	0 (3)	67 (9)	NT	100 (1)	60 (5)	0 (3)	0 (2)	50 (6)	20 (5)	50 (6)	NT	NT	NT	NT	NT	NT
	ICU	7	0 (6)	0 (2)	25 (4)	60 (5)	0 (5)	40 (5)	NT	NT	33 (3)	NT	0 (3)	0 (1)	0 (1)	0 (1)	NT	NT	NT	NT	0 (1)	NT
<i>Citrobacter freundii</i>	OPD	5	50 (2)	33 (3)	100 (3)	100 (5)	0 (1)	75 (4)	NT	NT	NT	NT	NT	50 (4)	33 (3)	20 (5)	NT	IR	IR	NT	NT	NT
	IPD	7	50 (6)	0 (1)	17 (6)	67 (3)	17 (6)	83 (6)	NT	NT	50 (4)	NT	33 (3)	100 (1)	NT	100 (1)	NT	IR	IR	NT	NT	NT
	ICU	3	0 (2)	0 (1)	0 (3)	NT	0 (2)	0 (2)	NT	NT	0 (3)	NT	0 (2)	NT	NT	NT	NT	IR	IR	NT	NT	NT
<i>Proteus mirabilis</i>	OPD	10	71 (7)	NT	100 (8)	75 (8)	33 (3)	NT	NT	NT	0 (2)	NT	100 (3)	100 (4)	50 (2)	IR	NT	NT	NT	IR	100 (1)	IR
	IPD	8	33 (6)	50 (2)	71 (7)	50 (4)	43 (7)	NT	NT	NT	60 (5)	NT	0 (3)	0 (1)	NT	IR	NT	75 (4)	100 (1)	IR	100 (1)	IR
	ICU	6	33 (3)	0 (1)	100 (2)	33 (3)	25 (4)	NT	NT	NT	25 (4)	NT	0 (3)	0 (1)	100 (1)	IR	NT	0 (2)	NT	IR	0 (1)	IR
<i>Proteus vulgaris</i>	OPD	4	100 (2)	50 (2)	100 (4)	75 (4)	100 (1)	100 (1)	NT	NT	NT	NT	NT	50 (2)	67 (3)	IR	NT	NT	0 (1)	IR	NT	IR
	IPD	7	14 (7)	NT	83 (6)	29 (7)	0 (2)	0 (1)	NT	NT	NT	NT	NT	0 (5)	0 (5)	IR	NT	0 (1)	NT	IR	NT	IR
	ICU	3	100 (1)	0 (1)	100 (1)	50 (2)	0 (2)	0 (1)	NT	NT	0 (2)	NT	0 (1)	NT	0 (1)	IR	NT	0 (2)	NT	IR	NT	IR
<i>Acinetobacter baumannii</i>	OPD	17	57 (7)	20 (5)	43 (7)	50 (12)	29 (14)	20 (10)	67 (3)	67 (3)	NT	IR	25 (4)	0 (1)	NBP	NBP	NT	IR	NT	NT	100 (4)	NT
	IPD	95	13 (55)	25 (12)	27 (55)	35 (51)	20 (64)	22 (32)	44 (23)	44 (23)	NT	IR	22 (54)	0 (4)	NBP	NBP	100 (4)	IR	13 (24)	100 (1)	25 (16)	100 (4)
	ICU	172	1 (104)	0 (33)	4 (103)	7 (109)	5 (148)	2 (110)	0 (31)	0 (31)	33 (3)	IR	4 (56)	13 (8)	NBP	NBP	100 (10)	IR	0 (33)	20 (10)	4 (26)	100 (10)

Gram-Negative Bacilli	Location	Isolates	Ceftriaxone %(n)	Cefotaxime %(n)	Ciprofloxacin %(n)	Imipenem %(n)	Meropenem %(n)	Chloramphenicol %(n)	Cotrimoxazole %(n)	Ampicillin %(n)	Pefloxacin %(n)	Azithromycin %(n)
<i>Salmonella Paratyphi A</i>	OPD	1	100 (1)	NT	NT	100 (1)	100 (1)	NT	NT	NT	NT	NBP
<i>Salmonella Typhi</i>	OPD	12	100 (12)	100 (1)	0 (12)	100 (10)	NT	92 (12)	89 (9)	91 (11)	22 (9)	100 (12)
	IPD	11	100 (11)	NT	10 (10)	100 (10)	100 (1)	100 (11)	90 (10)	100 (9)	0 (9)	100 (11)
<i>Salmonella Enterica</i>	OPD	3	100 (3)	NT	0 (3)	NT	NT	100 (3)	100 (3)	100 (3)	100 (3)	NBP
<i>Shigella spp.</i>	OPD	1	100 (1)	NT	0 (1)	100 (1)	NT	100 (1)	100 (1)	0 (1)	NBP	100 (1)
<i>Shigella sonnei</i>	IPD	1	0 (1)	0 (1)	0 (1)	100 (1)	NT	0 (1)	0 (1)	0 (1)	NBP	0 (1)


ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENS ISOLATED FROM MEDICINE DEPARTMENT JAN – DEC 2025



AST pattern of *Staphylococcus aureus* isolates from Medicine Department



AST pattern of *Escherichia coli* isolates from Medicine Department



**ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENS
ISOLATED FROM SURGERY DEPARTMENT
(JAN – DEC 2025)**

Antimicrobial susceptibility for Gram-positive pathogens from the Surgery department

[% of susceptible (total number of isolates tested for a given antibiotic) = %(n)]

Gram Positive Cocci	Location	No of isolates	Cefoxitin % (n)	Clindamycin % (n)	Erythromycin % (n)	Tetracycline % (n)	Chloramphenicol % (n)	Ciprofloxacin % (n)	Gentamicin % (n)	Trimethoprim/Sulfamethoxazole % (n)	Doxycycline % (n)	Linezolid % (n)	Nitrofurantoin % (n)	Ofloxacin % (n)	Norfloxacin % (n)
<i>Staphylococcus aureus</i>	OPD	249	49 (249)	64 (233)	13 (232)	61 (44)	94 (222)	50 (2)	68 (102)	64 (141)	100 (117)	100 (500)	100 (14)	18 (38)	75 (12)
	IPD	83	47 (83)	70 (82)	16 (82)	67 (21)	96 (72)	20 (5)	47 (17)	60 (64)	100 (40)	100 (27)	100 (1)	0 (2)	0 (1)
<i>MRSA</i>	OPD	124	0 (124)	54 (117)	9 (117)	50 (26)	92 (110)	0 (1)	57 (42)	57 (79)	100 (49)	100 (35)	100 (6)	5 (21)	60 (5)
	IPD	44	0 (44)	55 (44)	11 (44)	50 (8)	97 (38)	0 (4)	33 (6)	54 (35)	100 (20)	100 (15)	NT	0 (2)	NT
<i>MSSA</i>	OPD	125	100 (125)	75 (116)	16 (115)	78 (18)	96 (112)	100 (1)	75 (60)	73 (62)	100 (68)	100 (54)	100 (8)	35 (17)	86 (7)
	IPD	39	100 (39)	87 (38)	21 (38)	77 (13)	94 (34)	100 (1)	55 (11)	66 (29)	100 (20)	100 (11)	100 (1)	NT	0 (1)
<i>CONS</i>	OPD	6	17 (6)	33 (6)	17 (6)	50 (4)	80 (5)	NT	NT	0 (4)	NT	100 (5)	NT	NT	NT
	IPD	4	25 (4)	25 (4)	0 (4)	NT	100 (2)	NT	NT	50 (4)	NT	100 (4)	NT	NT	NT

Gram Positive Cocci	Location	No of isolates	Erythromycin%(n)	Linezolid%(n)	Tetracycline%(n)	Vancomycin%(n)	High level gentamicin %(n)	Chloramphenicol%(n)	Teicoplanin%(n)	Doxycycline % (n)	Ampicillin % (n)
<i>Enterococcus faecalis</i>	OPD	35	50 (4)	100 (27)	0 (11)	100 (35)	42 (23)	100 (6)	100 (12)	100 (1)	NT
	IPD	7	0 (5)	100 (3)	NT	100 (7)	29 (7)	67 (3)	100 (5)	NT	NT
<i>Enterococcus faecium</i>	OPD	22	20 (5)	100 (18)	0 (2)	100 (21)	86 (21)	100 (13)	100 (10)	NT	67 (3)
	IPD	12	0 (6)	100 (6)	0 (2)	100 (7)	73 (12)	100 (7)	88 (8)	NT	0 (2)
<i>Streptococcus pyogenes</i>	OPD	1	NT	100 (1)	0 (1)	100 (1)	NBP	NT	NT	NT	NT

Antimicrobial susceptibility for Gram-negative pathogens from the Surgery department


[% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]

Gram-Negative Bacilli	Location	Number of isolates	Ceftriaxone%(n)	Amoxicillin/clavulanic acid%(n)	Gentamicin%(n)	Ciprofloxacin%(n)	Piperacillin/Tazobactam%(n)	Amikacin%(n)	Tobramycin%(n)	Cotrimoxazole%(n)	Imipenem%(n)	Meropenem%(n)	Cefepime%(n)	Ceftazidime%(n)	Aztreonam%(n)	Cefixime%(n)	Norfloxacin%(n)	Ofloxacin%(n)	Nitrofurantoin%(n)	Cefotaxime%(n)	Tetracycline%(n)	Colistin%(n)
<i>Enterobacter species</i>	OPD	289	29 (207)	NT	63 (163)	21 (127)	44 (187)	52 (151)	NT	48 (108)	77 (202)	75 (4)	36 (28)	21 (117)	NT	9 (11)	42 (106)	27 (26)	66 (135)	33 (48)	15 (13)	100 (7)
	IPD	196	12 (139)	NT	56 (34)	9 (138)	17 (113)	42 (164)	100 (1)	41 (17)	41 (125)	80 (15)	13 (16)	9 (134)	NT	NT	36 (11)	20 (15)	63 (16)	19 (43)	0 (2)	100 (13)
<i>Escherichia coli</i>	OPD	213	31 (121)	27 (90)	64 (148)	18 (72)	60 (134)	57 (100)	NT	38 (97)	90 (133)	75 (8)	27 (26)	14 (44)	100 (1)	22 (9)	28 (103)	18 (17)	83 (130)	32 (66)	19 (31)	100 (3)
	IPD	100	15 (76)	9 (53)	56 (18)	3 (75)	18 (68)	54 (86)	NT	43 (7)	58 (74)	50 (4)	8 (13)	0 (36)	NT	NT	25 (4)	10 (10)	71 (7)	8 (12)	0 (1)	100 (4)
<i>Klebsiella pneumoniae</i>	OPD	98	34 (62)	23 (40)	72 (39)	21 (44)	49 (61)	44 (61)	NT	47 (32)	69 (64)	100 (1)	35 (17)	26 (46)	NT	67 (3)	71 (14)	29 (17)	31 (36)	35 (17)	40 (5)	100 (7)
	IPD	88	17 (66)	9 (45)	58 (12)	9 (67)	9 (56)	44 (78)	NT	17 (6)	43 (63)	60 (5)	20 (10)	19 (58)	NT	NT	25 (4)	11 (9)	17 (6)	25 (12)	NT	100 (10)
<i>Klebsiella oxytoca</i>	OPD	18	31 (16)	0 (1)	70 (10)	25 (8)	44 (18)	38 (8)	NT	40 (10)	65 (17)	NT	NT	100 (2)	NT	NT	50 (4)	NT	40 (10)	50 (2)	0 (1)	100 (1)
	IPD	14	22 (9)	0 (9)	0 (2)	13 (8)	43 (7)	17 (12)	NT	NT	71 (7)	0 (1)	25 (4)	25 (8)	NT	NT	NT	0 (4)	NT	0 (2)	NT	100 (1)
<i>Pseudomonas aeruginosa</i>	OPD	77	IR	IR	NBP	89 (35)	86 (42)	100 (3)	91 (74)	IR	97 (32)	33 (3)	100 (11)	95 (73)	98 (51)	NBP	80 (5)	100 (10)	NBP	IR	IR	100 (1)
	IPD	56	IR	IR	NBP	67 (12)	68 (38)	75 (4)	70 (54)	IR	74 (23)	80 (15)	100 (3)	79 (56)	74 (23)	NBP	NT	100 (3)	NBP	IR	IR	100 (5)


Gram-Negative Bacilli	Location	Number of isolates	Ceftriaxone%(n)	Gentamicin%(n)	Ciprofloxacin%(n)	Piperacillin/ Tazobactam%(n)	Amikacin%(n)	Cotrimoxazole%(n)	Imipenem%(n)	Meropenem%(n)	Cefepime%(n)	Ceftazidime%(n)	Norfloxacin%(n)	Ofloxacin%(n)	Nitrofurantoin%(n)	Cefotaxime%(n)	Minocycline%(n)	Ampicillin sulbactam%(n)	Colistin%(n)
<i>Proteus mirabilis</i>	OPD	51	66 (41)	49 (33)	20 (25)	87 (30)	45 (20)	43 (14)	NT	100 (1)	70 (10)	50 (6)	77 (13)	50 (10)	IR	25 (8)	NT	39 (13)	IR
	IPD	31	20 (20)	21 (24)	8 (24)	56 (18)	17 (6)	0 (2)	NT	75 (4)	50 (2)	50 (6)	NT	100 (2)	IR	30 (10)	0 (3)	43 (7)	IR
<i>Proteus vulgaris</i>	OPD	24	52 (23)	55 (20)	50 (8)	71 (17)	33 (3)	30 (10)	50 (6)	NT	100 (2)	100 (1)	33 (12)	100 (1)	IR	100 (3)	NT	67 (3)	IR
	IPD	13	46 (13)	56 (9)	40 (10)	70 (10)	0 (4)	0 (2)	71 (7)	NT	0 (2)	NT	0 (1)	0 (2)	IR	NT	0 (1)	50 (2)	IR
<i>Citrobacter freundii</i>	OPD	24	60 (15)	67 (12)	33 (12)	58 (19)	29 (14)	43 (7)	56 (18)	NT	0 (1)	33 (6)	43 (7)	0 (1)	38 (8)	25 (8)	NT	IR	NT
	IPD	10	40 (5)	40 (5)	29 (7)	17 (6)	50 (6)	NT	83 (6)	NT	NT	33 (6)	NT	NT	NT	0 (5)	NT	IR	NT
<i>Citrobacter koseri</i>	OPD	28	53 (19)	74 (23)	0 (6)	83 (18)	60 (5)	50 (18)	91 (22)	NT	50 (2)	50 (2)	53 (15)	50 (2)	94 (18)	50 (8)	NT	NT	NT
	IPD	22	26 (19)	50 (8)	18 (17)	37 (19)	64 (14)	50 (2)	68 (19)	50 (2)	NT	0 (5)	100 (1)	NT	100 (2)	0 (3)	100 (1)	NT	NT
<i>Citrobacter spp</i>	OPD	1	0 (1)	NT	NT	100 (1)	NT	0 (1)	100 (1)	NT	NT	NT	NT	NT	0 (1)	NT	NT	NT	NT
	IPD	1	0 (1)	NT	NT	100 (1)	NT	100 (1)	100 (1)	NT	NT	NT	0 (1)	NT	100 (1)	NT	NT	NT	NT
<i>Acinetobacter baumannii</i>	OPD	40	8 (24)	41 (22)	17 (23)	37 (19)	16 (19)	50 (2)	40 (20)	0 (1)	0 (8)	0 (13)	0 (3)	NBP	0 (3)	14 (7)	0 (3)	6 (18)	100 (1)
	IPD	60	9 (34)	13 (39)	9 (44)	5 (39)	12 (26)	14 (7)	5 (40)	0 (7)	0 (8)	0 (16)	NT	NBP	NT	0 (8)	25 (4)	6 (18)	100 (6)

ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENS ISOLATED FROM SURGERY DEPARTMENT JAN – DEC 2025


Distribution of bacterial isolates from Surgery department



AST Pattern of *Staphylococcus aureus* isolates in surgery department



AST pattern of *Escherichia coli* isolates from Surgery department



**ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENS
ISOLATED FROM PAEDIATRICS
DEPARTMENT
(JAN – DEC 2025)**

Antimicrobial susceptibility for Gram-positive pathogens from the Paediatrics department

[% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]

Gram-Positive Cocci	Location	Number of isolates	Cefoxitin %(n)	Gentamicin %(n)	Ciprofloxacin %(n)	Norfloxacin %(n)	Ofloxacin %(n)	Cotrimoxazole %(n)	Clindamycin %(n)	Vancomycin %(n)	Erythromycin %(n)	Nitrofurantoin %(n)	Linezolid %(n)	Minocycline %(n)
<i>Staphylococcus aureus</i>	OPD	29	61 (29)	84 (19)	79 (14)	50 (6)	0 (1)	85 (13)	59 (22)	100 (2)	29 (21)	100 (7)	100 (17)	NT
	IPD	97	51 (97)	92 (82)	59 (49)	25 (4)	0 (3)	52 (54)	62 (84)	100 (1)	19 (81)	100 (4)	100 (51)	100 (7)
	ICU	59	54 (59)	78 (46)	32 (31)	NT	0 (1)	74 (39)	43 (56)	100 (1)	16 (55)	NT	100 (31)	100 (6)
<i>MRSA</i>	OPD	11	0 (11)	63 (8)	33 (3)	50 (4)	0 (1)	67 (3)	29 (7)	NT	0 (7)	NT	NT	NT
	IPD	46	0 (46)	85 (39)	46 (24)	0 (2)	0 (2)	33 (21)	47 (43)	NT	5 (41)	NT	NT	NT
	ICU	27	0 (27)	71 (24)	14 (14)	NT	NT	53 (15)	22 (27)	100 (1)	0 (26)	NT	100 (15)	100 (3)
<i>MSSA</i>	OPD	18	100 (18)	87 (22)	91 (11)	50 (2)	NT	90 (10)	73 (15)	NT	43 (14)	100 (3)	100 (9)	NT
	IPD	51	100 (51)	98 (43)	72 (25)	50 (2)	0 (1)	64 (33)	78 (41)	NT	33 (40)	100 (2)	100 (23)	100 (5)
	ICU	32	100 (32)	87 (22)	47 (17)	NT	0 (1)	88 (24)	62 (29)	NT	31 (29)	NT	100 (16)	100 (3)

Gram-Positive Cocci	Location	Number of isolates	Gentamicin (120) %(n)	Erythromycin %(n)	Linezolid %(n)	Norfloxacin %(n)	Nitrofurantoin%(n)	Ampicillin %(n)	Ciprofloxacin %(n)	Vancomycin %(n)	Teicoplanin %(n)
<i>Enterococcus faecalis</i>	OPD	15	71 (14)	NT	100 (12)	33 (3)	86 (14)	NT	22 (9)	100 (15)	71 (7)
	IPD	12	67 (12)	0 (1)	100 (9)	33 (3)	88 (8)	50 (2)	0 (5)	100 (18)	100 (6)
	ICU	10	50 (10)	0 (4)	100 (8)	0 (1)	50 (2)	0 (1)	0 (2)	100 (6)	83 (6)
<i>Enterococcus faecium</i>	OPD	20	74 (19)	0 (2)	100 (19)	0 (4)	89 (18)	67 (6)	15 (13)	100 (17)	100 (8)
	IPD	16	64 (14)	0 (3)	100 (16)	0 (1)	71 (7)	33 (3)	0 (6)	100 (13)	92 (13)
	ICU	6	67 (6)	0 (3)	100 (6)	NT	NT	67 (3)	0 (1)	100 (5)	100 (3)
<i>Enterococcus spp.</i>	OPD	36	74 (34)	0 (2)	100 (32)	100 (33)	88 (33)	67 (6)	17 (23)	100 (33)	87 (15)
	IPD	29	67 (27)	0 (4)	100 (25)	100 (22)	80 (15)	40 (5)	0 (11)	100 (22)	95 (20)
	ICU	17	53 (17)	0 (7)	100 (15)	0 (1)	50 (2)	50 (4)	0 (3)	100 (11)	90 (10)

Antimicrobial susceptibility for Gram-negative pathogens from the Paediatrics department
[% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]


Gram-negative bacilli	Location	Number of isolates	Ampicillin %(n)	Amoxicillin + Clavulanic acid %(n)	Piperacillin + Tazobactam %(n)	Ceftazidime %(n)	Ceftriaxone %(n)	Cefotaxime %(n)	Cefepime %(n)	Cefixime %(n)	Imipenem %(n)	Meropenem %(n)	Amikacin %(n)	Gentamicin %(n)	Ciprofloxacin %(n)	Norfloxacin %(n)	Cotrimoxazole %(n)	Nitrofurantoin %(n)	Colistin %(n)
<i>Klebsiella oxytoca</i>	OPD	9	IR	0 (1)	38 (8)	NT	33 (9)	NT	NT	NT	89 (9)	NT	NT	89 (9)	NT	100 (2)	56 (9)	56 (9)	NT
	IPD	5	IR	NT	0 (4)	NT	25 (4)	NT	NT	NT	60 (5)	NT	NT	40 (5)	NT	50 (4)	25 (4)	20 (5)	NT
	ICU	1	IR	100 (1)	NT	100 (1)	100 (1)	NT	NT	NT	100 (1)	NT	100 (1)	NT	100 (1)	NT	NT	NT	NT
<i>Klebsiella pneumoniae</i>	OPD	22	IR	20 (5)	50 (18)	0 (2)	63 (19)	33 (3)	NT	NT	43 (14)	NT	33 (3)	90 (19)	0 (3)	82 (11)	73 (15)	15 (20)	100 (1)
	IPD	18	IR	11 (9)	25 (16)	10 (10)	7 (14)	17 (6)	0 (2)	NT	70 (20)	100 (1)	38 (8)	22 (9)	11 (9)	33 (6)	0 (5)	13 (8)	100 (1)
	ICU	47	IR	11 (18)	16 (25)	5 (19)	6 (36)	6 (17)	NT	NT	36 (17)	39 (13)	27 (41)	80 (25)	14 (29)	0 (1)	60 (5)	0 (3)	100 (8)
<i>Escherichia coli</i>	OPD	145	21 (34)	29 (38)	54 (81)	25 (4)	35 (94)	31 (71)	100 (1)	26 (23)	99 (54)	100 (1)	65 (69)	70 (103)	27 (55)	30 (72)	32 (85)	92 (82)	100 (1)
	IPD	84	15 (40)	3 (16)	50 (50)	42 (12)	22 (69)	8 (37)	20 (5)	36 (14)	78 (40)	78 (9)	77 (56)	64 (39)	11 (53)	6 (16)	22 (45)	74 (19)	100 (2)
	ICU	19	33 (6)	NT	23 (13)	17 (6)	20 (15)	0 (4)	50 (6)	NT	83 (6)	67 (6)	44 (16)	80 (10)	17 (6)	0 (3)	0 (2)	60 (5)	NT
<i>Enterobacter spp.</i>	OPD	129	IR	NT	56 (77)	75 (8)	37 (90)	29 (35)	100 (3)	38 (8)	80 (88)	67 (3)	64 (33)	71 (115)	14 (21)	38 (79)	29 (85)	66 (111)	NT
	IPD	67	IR	NT	40 (50)	48 (25)	20 (51)	25 (20)	67 (3)	0 (1)	54 (43)	80 (10)	56 (36)	70 (40)	26 (31)	4 (24)	20 (20)	66 (29)	100 (2)
	ICU	60	IR	NT	14 (36)	3 (29)	10 (50)	0 (11)	43 (7)	NT	24 (37)	20 (10)	40 (52)	68 (31)	11 (45)	0 (5)	33 (3)	33 (6)	100 (1)
<i>Acinetobacter baumannii</i>	OPD	10	IR	IR	100 (4)	0 (1)	33 (6)	0 (3)	50 (2)	NT	16 (38)	0 (12)	75 (4)	60 (10)	40 (5)	NT	50 (2)	0 (1)	100 (1)
	IPD	38	IR	IR	37 (27)	32 (22)	15 (20)	10 (10)	33 (6)	NT	40 (20)	25 (8)	46 (24)	40 (20)	28 (25)	0 (1)	NT	0 (2)	NT
	ICU	71	IR	IR	12 (43)	13 (32)	4 (50)	0 (13)	21 (19)	NT	16 (38)	0 (2)	12 (51)	3 (36)	15 (40)	NT	0 (2)	NT	100 (6)

Gram-Negative Bacilli	Location	Number of isolates	Amoxicillin + Clavulanic Acid %(n)	Piperacillin + Tazobactam %(n)	Ceftazidime %(n)	Ceftriaxone %(n)	Cefotaxime %(n)	Imipenem %(n)	Meropenem %(n)	Amikacin %(n)	Gentamicin %(n)	Ciprofloxacin %(n)	Norfloxacin %(n)	Cotrimoxazole %(n)	Nitrofurantoin %(n)	Tobramycin %(n)	Aztreonam %(n)
<i>Citrobacter freundii</i>	OPD	6	IR	40 (5)	0 (1)	100 (3)	0 (3)	80 (5)	100 (1)	33 (3)	75 (4)	0 (2)	67 (3)	100 (4)	75 (4)	NT	NT
	IPD	4	IR	50 (4)	67 (3)	67 (3)	100 (1)	100 (4)	NT	67 (3)	100 (1)	67 (3)	NT	0 (1)	100 (1)	NT	NT
	ICU	3	IR	33 (3)	100 (1)	0 (3)	NT	67 (3)	NT	100 (1)	0 (2)	0 (1)	0 (1)	NT	100 (1)	NT	NT
<i>Citrobacter koseri</i>	OPD	8	IR	20 (5)	NT	29 (7)	NT	88 (8)	NT	NT	71 (7)	NT	14 (7)	0 (5)	75 (8)	NT	NT
	IPD	8	IR	86 (7)	100 (2)	60 (5)	67 (3)	100 (8)	NT	100 (4)	80 (5)	50 (4)	25 (4)	0 (4)	33 (3)	NT	NT
	ICU	2	IR	50 (2)	0 (2)	50 (2)	NT	100 (2)	NT	50 (2)	NT	50 (2)	NT	NT	NT	NT	NT
<i>Pseudomonas aeruginosa</i>	OPD	3	IR	50 (2)	100 (2)	IR	IR	100 (2)	100 (1)	NT	NBP	NT	100 (1)	IR	NT	100 (1)	100 (2)
	IPD	9	IR	100 (8)	89 (9)	IR	IR	100 (8)	100 (2)	67 (3)	NBP	NT	NT	IR	NT	60 (5)	83 (6)
	ICU	5	IR	67 (3)	80 (5)	IR	IR	100 (3)	NT	100 (4)	NBP	NT	NT	IR	NT	75 (4)	100 (4)
<i>Proteus mirabilis</i>	OPD	8	20 (5)	100 (3)	NT	75 (4)	75 (4)	NT	100 (1)	100 (3)	75 (8)	0 (1)	83 (6)	33 (6)	IR	NT	NT
	IPD	6	50 (2)	100 (4)	100 (2)	67 (3)	0 (2)	NT	NT	33 (3)	20 (5)	100 (1)	75 (4)	33 (3)	IR	NT	NT
	ICU	1	0 (1)	100 (1)	0 (1)	100 (1)	NT	NT	NT	0 (1)	NT	100 (1)	NT	NT	IR	NT	NT
<i>Proteus vulgaris</i>	OPD	9	0 (1)	100 (8)	NT	50 (4)	50 (2)	100 (1)	NT	NT	78 (9)	NT	29 (7)	25 (8)	IR	NT	NT
	ICU	1	NT	100 (1)	NT	NT	NT	NT	NT	NT	100 (1)	100 (1)	NT	NT	IR	NT	NT


Gram-Negative Bacilli	Location	Number Of Isolates	Ampicillin %(n)	Ceftriaxone %(n)	Cefotaxime %(n)	Cefepime %(n)	Imipenem %(n)	Meropenem %(n)	Ciprofloxacin %(n)	Cotrimoxazole %(n)	Chloramphenicol %(n)	Tetracycline %(n)	Pefloxacin %(n)	Azithromycin %(n)
<i>Salmonella Typhi</i>	OPD	15	100 (14)	100 (15)	100 (2)	0 (4)	100 (14)	NT	0 (15)	100 (10)	100 (15)	NT	14 (7)	100 (15)
	IPD	49	92 (36)	100 (49)	80 (5)	0 (4)	100 (45)	100 (6)	11 (47)	93 (43)	96 (47)	NT	9 (34)	100 (49)
	ICU	1	100 (1)	100 (1)	NT	NT	100 (1)	NT	0 (1)	100 (1)	100 (1)	NT	0 (1)	100 (1)
<i>Salmonella enterica subspp enterica</i>	OPD	3	100 (3)	100 (3)	NT	NT	NT	NT	0 (3)	100 (3)	100 (3)	NT	100 (3)	NBP
	IPD	2	100 (2)	100 (2)	NT	NT	NT	NT	0 (2)	100 (2)	100 (2)	NT	50 (2)	NBP
	ICU	2	100 (2)	100 (2)	NT	NT	NT	NT	0 (2)	100 (2)	100 (2)	NT	100 (2)	NBP
<i>Salmonella Enteritidis</i>	OPD	1	100 (1)	100 (1)	NT	NT	100 (1)	NT	0 (1)	100 (1)	NT	NT	NT	NBP
	IPD	1	0 (1)	0 (1)	NT	0 (1)	100 (1)	NT	0 (1)	100 (1)	100 (1)	NT	NT	NBP
<i>Shigella spp.</i>	OPD	5	0 (4)	0 (5)	0 (2)	NT	100 (2)	NT	0 (4)	0 (5)	100 (2)	NT	NT	50 (4)
	IPD	1	0 (1)	0 (1)	NT	NT	NT	NT	100 (1)	NT	100 (1)	NT	NT	0 (1)
<i>Vibrio cholerae</i>	IPD	1	NT	NT	NT	NT	NT	NT	NT	100 (1)	100 (1)	100 (1)	NT	100 (1)

ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENS ISOLATED FROM PAEDIATRICS DEPARTMENT JAN – DEC 2025


Distribution of Bacterial isolates from Pediatrics Department



AST Pattern of *Staphylococcus aureus* in Paediatrics departmet



AST Pattern of *Escherichia coli* isolates in Paediatrics department



**ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENS
ISOLATED FROM ORTHOPAEDICS
DEPARTMENT
(JAN – DEC 2025)**

Antimicrobial susceptibility for gram positive pathogens from Orthopaedics department
 [% of susceptible (total number of isolates tested for a given antibiotic) = %(n)]

Gram Positive Cocci	Location	No of isolates	Cefoxitin %(n)	Clindamycin %(n)	Erythromycin %(n)	Tetracycline %(n)	Chloramphenicol %(n)	Gentamicin %(n)	Trimethoprim/Sulfamethoxazole %(n)	Doxycycline %(n)	Linezolid %(n)	Ofloxacin %(n)
<i>Staphylococcus aureus</i>	OPD	96	39 (96)	72 (96)	15 (96)	62 (21)	97 (86)	69 (13)	62 (84)	100 (52)	100 (24)	0 (5)
	IPD	133	46 (133)	64 (132)	17 (132)	63 (19)	91 (115)	62 (39)	53 (91)	99 (66)	100 (21)	23 (13)
<i>MRSA</i>	OPD	58	0 (58)	64 (58)	14 (58)	73 (15)	98 (51)	57 (7)	60 (52)	100 (29)	100 (17)	0 (4)
	IPD	74	0 (74)	60 (74)	11 (74)	67 (9)	90 (66)	47 (19)	50 (50)	97 (39)	100 (17)	13 (8)
<i>MSSA</i>	OPD	38	100 (38)	84 (38)	16 (38)	33 (6)	94 (35)	83 (6)	66 (32)	100 (23)	100 (7)	0 (1)
	IPD	59	100 (59)	71 (58)	24 (58)	60 (10)	96 (49)	75 (20)	56 (41)	100 (27)	100 (9)	40 (5)




Gram Positive Cocci	Location	No of isolates	Erythromycin%(n)	Clindamycin % (n)	Linezolid%(n)	Tetracycline%(n)	Vancomycin%(n)	High level gentamicin%(n)	Chloramphenicol%(n)	Ciprofloxacin%(n)	Teicoplanin %(n)	Norfloxacina%(n)	Nitrofurantoin%(n)	Doxycycline % (n)
<i>Enterococcus faecalis</i>	IPD	5	0 (3)	IR	100 (3)	0 (2)	100 (4)	20 (5)	100 (2)	0 (2)	100 (2)	0 (1)	50 (2)	100 (1)
<i>Enterococcus faecium</i>	IPD	5	0 (2)	IR	100 (1)	NT	100 (5)	60 (5)	100 (2)	NT	75 (4)	NT	100 (1)	NT
<i>Streptococcus pyogenes</i>	IPD	1	100 (1)	100 (1)	100 (1)	NT	100 (1)	NBP	NT	NBP	NBP	NBP	NBP	NBP

Antimicrobial susceptibility for Gram-negative pathogens from the Orthopaedics department
 [% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]

Gram-Negative Bacteria	Location	No of isolates	Cefotaxime%(n)	Ceftriaxone%(n)	Amoxicillin/clavulanic acid%(n)	Piperacillin/tazobactam%(n)	Gentamicin%(n)	Ciprofloxacin%(n)	Imipenem%(n)	Meropenem%(n)	Ofloxacin %(n)	Amikacin%(n)	Cefixime %(n)	Ceftazidime%(n)	Cefepime %(n)	Norfloxacin%(n)	Nitrofurantoin%(n)	Trimethoprim/Sulphamethoxazole%(n)	Minocycline % (n)	Ampicillin/ Sulbactam % (n)	Colistin % (n)
<i>Enterobacter spp.</i>	OPD	41	NT	18 (38)	NT	28 (32)	31 (13)	22 (32)	49 (33)	NT	25 (4)	55 (29)	100 (1)	13 (30)	25 (4)	0 (2)	67 (3)	33 (3)	100 (1)	IR	100 (3)
	IPD	140	14 (14)	13 (111)	NT	26 (74)	42 (36)	14 (107)	42 (97)	50 (2)	0 (10)	42 (109)	NT	12 (86)	8 (12)	21 (14)	41 (17)	14 (21)	100 (1)	IR	100 (6)
<i>Escherichia coli</i>	OPD	12	0 (1)	18 (11)	0 (9)	20 (10)	100 (2)	9 (11)	50 (10)	100 (1)	NT	36 (11)	NT	0 (2)	NT	NT	100 (2)	100 (1)	NT	NT	NT
	IPD	47	20 (10)	19 (26)	13 (24)	21 (24)	80 (100)	18 (53)	56 (25)	67 (3)	0 (3)	53 (38)	0 (1)	13 (23)	25 (4)	44 (9)	80 (10)	67 (9)	NT	40 (5)	100 (2)
<i>Klebsiella pneumoniae</i>	OPD	8	0 (2)	0 (5)	0 (1)	0 (6)	0 (1)	17 (6)	50 (6)	0 (1)	100 (1)	14 (7)	100 (1)	25 (40)	NT	0 (1)	NT	0 (1)	NT	NT	100 (1)
	IPD	61	0 (7)	14 (43)	18 (28)	10 (31)	0 (10)	12 (49)	47 (34)	0 (5)	0 (5)	32 (56)	0 (4)	11 (44)	0 (6)	0 (4)	0 (5)	0 (3)	NT	0 (2)	100 (7)
<i>Klebsiella oxytoca</i>	OPD	2	NT	0 (2)	NT	0 (2)	NT	0 (2)	0 (2)	NT	NT	0 (2)	NT	0 (1)	NT	NT	NT	NT	NT	NT	NT
	IPD	1	NT	0 (1)	NT	NT	NT	0 (1)	0 (1)	NT	NT	100 (1)	NT	0 (1)	NT	NT	NT	NT	NT	NT	NT
<i>Acinetobacter baumannii</i>	OPD	10	0 (1)	0 (7)	IR	17 (6)	13 (8)	11 (9)	13 (8)	50 (2)	NT	0 (3)	IR	0 (5)	NT	NT	IR	50 (2)	100 (2)	25 (4)	100 (2)
	IPD	56	20 (5)	3 (40)	IR	6 (33)	16 (31)	6 (47)	7 (31)	0 (6)	NT	12 (34)	IR	12 (25)	0 (7)	NT	IR	0 (3)	60 (5)	14 (22)	100 (5)

Gram-Negative Bacteria	Location	No of isolates	Cefotaxime % (n)	Ceftriaxone % (n)	Piperacillin/tazobactam % (n)	Gentamicin % (n)	Ciprofloxacin % (n)	Imipenem % (n)	Meropenem % (n)	Amikacin % (n)	Ceftazidime % (n)	Ofloxacin % (n)	Norfloxacin % (n)	Cefepime % (n)	Ampicillin/Sulbactam % (n)
<i>Citrobacter koseri</i>	OPD	1	NT	0 (1)	100 (1)	NT	100 (1)	0 (1)	NT	0 (1)	NT	NT	50 (1)	NT	NT
	IPD	18	0 (3)	0 (14)	18 (1)	50 (6)	8 (13)	50 (10)	50 (2)	42 (12)	10 (10)	100 (1)	0 (2)	NT	NT
<i>Citrobacter freundii</i>	OPD	1	0 (1)	NT	0 (1)	NT	0 (1)	0 (1)	NT	0 (1)	0 (1)	NT	NT	NT	IR
	IPD	8	100 (2)	34 (6)	67 (6)	100 (4)	60 (5)	60 (5)	NT	50 (4)	0 (2)	100 (2)	NT	0 (2)	IR
<i>Citrobacter spp.</i>	OPD	1	NT	0 (1)	0 (1)	NT	0 (1)	0 (1)	NT	0 (1)	NT	NT	NT	NT	NT
	IPD	1	NT	100 (1)	100 (1)	NT	0 (1)	100 (1)	NT	100 (1)	100 (1)	NT	NT	NT	NT
<i>Proteus mirabilis</i>	OPD	8	NT	29 (7)	75 (8)	40 (5)	14 (7)	NT	NT	100 (3)	0 (4)	NT	NT	NT	0 (1)
	IPD	14	100 (2)	33 (12)	50 (8)	30 (10)	9 (11)	NT	NT	80 (5)	75 (4)	100 (1)	NT	100 (1)	0 (3)
<i>Proteus vulgaris</i>	OPD	1	NT	100 (1)	100 (1)	NT	0 (1)	100 (1)	NT	100 (1)	NT	NT	NT	NT	NT
	IPD	2	NT	0 (1)	0 (2)	0 (1)	50 (2)	0 (1)	NT	100 (2)	0 (1)	NT	NT	NT	NT

Gram-Negative Bacteria	Location	No of isolates	Cefepime %(n)	Piperacillin/tazobactam %(n)	Gentamicin %(n)	Ciprofloxacin %(n)	Imipenem %(n)	Meropenem %(n)	Tobramycin %(n)	Amikacin %(n)	Ceftazidime %(n)	Ofloxacin %(n)	Norfloxacin % (n)	Aztreonam % (n)	Netilmicin % (n)	Colistin % (n)
<i>Pseudomonas aeruginosa</i>	OPD	17	100 (2)	83 (12)	NT	67 (3)	100 (10)	100 (1)	88 (17)	NT	88 (17)	100 (2)	NT	100 (14)	100 (7)	NT
	IPD	37	88 (8)	68 (19)	33 (3)	57 (14)	83 (18)	0 (1)	74 (34)	50 (2)	74 (35)	75 (8)	0 (1)	74 (19)	87 (23)	100 (2)



**ANTIBIOTIC SUSCEPTIBILITY OF
PATHOGENS ISOLATED FROM
OPHTHALMOLOGY DEPARTMENT
(JAN – DEC 2025)**

Antimicrobial susceptibility for Gram-positive pathogens from the Ophthalmology department

[% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]



Gram Positive Cocci	location	Isolates	Erythromycin %(n)	Clindamycin %(n)	Tetracycline %(n)	Cotrimoxazole %(n)	Cefoxitin %(n)	Ciprofloxacin %(n)	Linezolid %(n)	Chloramphenicol %(n)	Gentamycin %(n)	Doxycycline % (n)	Ofloxacin % (n)
<i>Staphylococcus aureus</i>	OPD	1	0 (1)	NT	NT	NT	100 (1)	NT	NT	0 (1)	NT	100 (1)	NT
	IPD	8	13 (8)	63 (8)	100 (2)	80 (5)	50 (8)	0 (1)	100 (2)	83 (6)	75 (4)	100 (4)	0 (2)
<i>MRSA</i>	IPD	4	0 (4)	50 (4)	100 (2)	67 (3)	0 (4)	NT	100 (1)	100 (3)	50 (2)	100 (2)	0 (1)
<i>MSSA</i>	OPD	1	0 (1)	NT	NT	NT	100 (1)	NT	NT	0 (1)	NT	100 (1)	NT
	IPD	4	25 (4)	75 (4)	100 (1)	100 (2)	100 (4)	0 (1)	100 (1)	67 (3)	100 (2)	100 (2)	0 (1)
<i>CONS</i>	IPD	1	0 (1)	0 (1)	NT	0 (1)	0 (1)	NT	100 (1)	100 (1)	NT	NT	NT

Antimicrobial susceptibility for Gram-negative pathogens from the Ophthalmology department

[% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]

Gram-Negative Bacilli	Location	Isolates	Cefotaxime %(n)	Cefepime %(n)	Amikacin %(n)	Ciprofloxacin %(n)	Piperacillin/tazobactam %(n)	Ceftioxone %(n)	Imipenem %(n)	Ceftazidime %(n)	Meropenem %(n)	Netilmicin % (n)	Aztreonam % (n)	Tobramycin % (n)
<i>Pseudomonas aeruginosa</i>	IPD	3	NT	100 (1)	100 (1)	100 (2)	100 (2)	IR	100 (2)	100 (3)	0 (1)	100 (3)	100 (1)	100 (2)
<i>Enterobacter spp.</i>	IPD	2	100 (2)	NT	100 (1)	0 (2)	NT	NT	100 (2)	100 (1)	NT	NT	NT	NT
<i>Citrobacter koseri</i>	IPD	1	NT	NT	100 (1)	0 (1)	NT	0 (1)	NT	100 (1)	NT	NT	NT	NT

ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENS ISOLATED FROM OPHTHALMOLOGY DEPARTMENT JAN – DEC 2025



**ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENS
ISOLATED FROM ENT DEPARTMENT
(JAN – DEC 2025)**

Antimicrobial susceptibility for Gram-positive pathogens from ENT department
 [% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]

Gram-positive cocci	location	Isolates	Erythromycin %(n)	Clindamycin %(n)	Tetracycline %(n)	Cotrimoxazole %(n)	Cefoxitin %(n)	Gentamicin %(n)	Linezolid %(n)	High Level Gentamicin %(n)	Chloramphenicol %(n)	Vancomycin %(n)	Teicoplanin %(n)
<i>Staphylococcus aureus</i>	OPD	171	11 (171)	68 (171)	58 (24)	70 (130)	49 (171)	46 (33)	100 (35)	NT	95 (147)	NT	NT
	IPD	29	10 (29)	62 (29)	50 (2)	77 (13)	48 (29)	50 (8)	100 (5)	NT	100 (22)	NT	NT
<i>MRSA</i>	OPD	88	8 (88)	62 (88)	40 (10)	62 (66)	0 (88)	29 (17)	100 (18)	NT	96 (71)	NT	NT
	IPD	15	0 (15)	60 (15)	NT	100 (5)	0 (15)	25 (4)	100 (2)	NT	100 (11)	NT	NT
<i>MSSA</i>	OPD	83	13 (83)	74 (83)	71 (14)	78 (64)	100 (83)	63 (16)	100 (17)	NT	95 (76)	NT	NT
	IPD	14	21 (14)	64 (14)	50 (2)	63 (8)	100 (14)	75 (4)	100 (3)	NT	100 (11)	NT	NT
<i>CONS</i>	OPD	3	33 (3)	67 (3)	100 (1)	67 (3)	67 (3)	NT	100 (3)	NT	50 (2)	NT	NT
	IPD	1	0 (1)	100 (1)	0 (1)	100 (1)	0 (1)	NT	100 (1)	NT	100 (1)	NT	NT
<i>Enterococcus faecalis</i>	OPD	1	0 (1)	IR	NT	IR	NT	NT	NT	0 (1)	NT	100 (1)	NT
	IPD	2	NT	IR	NT	IR	NT	NT	100 (2)	50 (2)	NT	100 (1)	NT
<i>Enterococcus faecium</i>	OPD	3	0 (3)	IR	NT	IR	NT	NT	NT	100 (3)	100 (3)	100 (2)	100 (3)
	IPD	1	NT	IR	NT	IR	NT	NT	NT	100 (1)	100 (1)	NT	100 (1)
<i>Streptococcus pyogenes</i>	OPD	1	100 (1)	100 (1)	NT	NT	NT	NT	100 (1)	NT	NT	NT	NT

Antimicrobial susceptibility for Gram-negative pathogens from ENT department


[% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]

Gram-Negative Bacteria	Location	No of isolates	Cefotaxime%(n)	Ceftriaxone%(n)	Amoxicillin/ clavulanic acid%(n)	Piperacillin/tazobactam %(n)	Gentamicin%(n)	Ciprofloxacin%(n)	Imipenem%(n)	Meropenem%(n)	Tobramycin%(n)	Amikacin%(n)	Aztreonam%(n)	Ceftazidime%(n)	Trimethoprim/ Sulphamethoxazole%(n)
<i>Escherichia coli</i>	OPD	6	NT	40 (5)	25 (4)	50 (4)	NT	17 (6)	100 (3)	NT	NT	83 (6)	NT	25 (4)	0 (1)
	IPD	13	50 (2)	33 (6)	25 (4)	25 (4)	60 (5)	0 (5)	80 (5)	100 (1)	NT	33 (9)	NT	11 (9)	33 (3)
<i>Enterobacter spp.</i>	OPD	39	67 (3)	31 (9)	NT	37 (24)	71 (7)	21 (28)	61 (26)	100 (1)	NT	62 (32)	NT	34 (29)	0 (1)
	IPD	16	0 (4)	22 (9)	NT	14 (7)	33 (6)	0 (4)	33 (6)	NT	NT	18 (11)	NT	12 (8)	33 (3)
<i>Pseudomonas aeruginosa</i>	OPD	66	IR	IR	NT	92 (49)	100 (3)	87 (15)	95 (39)	62 (8)	80 (65)	100 (2)	98 (50)	91 (64)	IR
	IPD	12	IR	IR	NT	71 (7)	NT	NT	100 (4)	75 (4)	68 (12)	NT	100 (3)	83 (12)	IR
<i>Klebsiella pneumoniae</i>	OPD	19	50 (2)	64 (14)	57 (14)	43 (14)	50 (4)	33 (15)	94 (16)	NT	NT	80 (15)	NT	67 (15)	0 (1)
	IPD	5	NT	25 (4)	0 (3)	0 (4)	NT	33 (3)	50 (4)	NT	NT	20 (5)	NT	25 (4)	NT
<i>Klebsiella oxytoca</i>	OPD	1	NT	0 (1)	NT	0 (1)	NT	0 (1)	0 (1)	NT	NT	0 (1)	NT	0 (1)	NT
<i>Acinetobacter baumannii</i>	OPD	4	NT	50 (2)	IR	50 (2)	100 (2)	25 (4)	100 (2)	0 (1)	NT	0 (2)	IR	0 (2)	NT
	IPD	7	NT	0 (5)	IR	25 (4)	25 (4)	20 (5)	25 (4)	NT	NT	0 (3)	IR	0 (2)	NT


Gram-Negative Bacteria	Location	No of isolates	Cefotaxime%(n)	Ceftriaxone%(n)	Piperacillin/tazobactam%(n)	Gentamicin%(n)	Ciprofloxacin%(n)	Imipenem%(n)	Meropenem%(n)	Amikacin%(n)	Ceftazidime%(n)
<i>Citrobacter spp</i>	IPD	1	0 (1)	NT	0 (1)	0 (1)	NT	NT	NT	NT	NT
<i>Citrobacter koseri</i>	OPD	2	NT	0 (2)	0 (2)	NT	0 (1)	50 (2)	NT	100 (2)	0 (1)
	IPD	1	NT	100 (1)	0 (1)	100 (1)	100 (1)	100 (1)	NT	NT	NT
<i>Citrobacter freundii</i>	OPD	4	100 (1)	67 (3)	67 (3)	67 (3)	100 (4)	67 (3)	100 (1)	100 (1)	NT
	IPD	1	NT	0 (1)	0 (1)	NT	0 (1)	100 (1)	NT	0 (1)	100 (1)
<i>Proteus vulgaris</i>	OPD	9	100 (1)	63 (8)	80 (5)	20 (5)	20 (5)	67 (3)	NT	67 (3)	33 (3)
	IPD	2	0 (2)	NT	NT	50 (2)	0 (1)	NT	0 (1)	NT	0 (1)
<i>Proteus mirabilis</i>	OPD	12	50 (2)	50 (10)	100 (7)	40 (10)	13 (8)	NT	NT	50 (2)	67 (3)
	IPD	1	NT	100 (1)	100 (1)	0 (1)	100 (1)	NT	NT	NT	NT

ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENS ISOLATED FROM ENT DEPARTMENT JAN – DEC 2025


Distribution of bacterial isolates from ENT department



AST pattern of *Staphylococcus aureus* isolates from ENT department



AST pattern of *Pseudomonas aeruginosa* from ENT department



**ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENS
ISOLATED FROM DERMATOLOGY
DEPARTMENT
(JAN – DEC 2025)**

Antimicrobial susceptibility for Gram-positive pathogens from the Dermatology department




[% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]

Gram Positive Cocci	Location	Number	Cefoxitin %(n)	Cotrimoxazole %(n)	Clindamycin %(n)	Erythromycin %(n)	Linezolid %(n)	Doxycycline %(n)	Vancomycin %(n)	Tetracycline %(n)	High level gentamicin %(n)	Chloramphenicol %(n)	Ciprofloxacin %(n)	Gentamicin %(n)
<i>Staphylococcus aureus</i>	OPD	87	49 (87)	60 (57)	NT	NT	100 (12)	98 (46)	NT	51 (53)	NT	92 (76)	0 (1)	68 (31)
	IPD	19	37 (19)	14 (57)	NT	NT	100 (7)	100 (8)	NT	50 (4)	NT	100 (15)	0 (2)	50 (2)
<i>MRSA</i>	OPD	44	0 (44)	63 (32)	59 (41)	7 (41)	100 (6)	96 (22)	NT	63 (8)	NT	90 (39)	0 (1)	40 (15)
	IPD	12	0 (12)	56 (9)	83 (12)	0 (12)	100 (7)	100 (4)	NT	33 (3)	NT	100 (10)	0 (2)	50 (2)
<i>MSSA</i>	OPD	43	100 (43)	56 (25)	80 (40)	20 (40)	100 (6)	100 (24)	NT	40 (5)	NT	95 (37)	NT	94 (16)
	IPD	7	100 (7)	60 (5)	71 (7)	14 (7)	NT	100 (4)	NT	100 (1)	NT	100 (5)	NT	NT
<i>CONS</i>	IPD	1	0 (1)	0 (1)	0 (1)	0 (1)	NT	100 (1)	NT	0 (1)	NT	100 (1)	NT	NT
<i>Enterococcus faecalis</i>	OPD	1	NT	IR	IR	NT	NT	NT	100 (1)	NT	0 (1)	NT	NT	IR
<i>Enterococcus faecium</i>	OPD	1	NT	IR	IR	NT	100 (1)	NT	100 (1)	NT	100 (1)	NT	NT	IR

Antimicrobial susceptibility for Gram-negative pathogens from the Dermatology department

Gram-Negative Bacilli	Location	Number of isolates	Piperacillin/tazobactam % (n)	Ceftazidime % (n)	Aztreonam % (n)	Imipenem % (n)	Gentamicin % (n)	Tobramycin % (n)	Ciprofloxacin % (n)	Norfloxacin % (n)	Ceftioxone % (n)	Amikacin % (n)	Co-trimoxazole % (n)
<i>Escherichia coli</i>	OPD	10	50 (6)	NT	NT	83 (6)	50 (8)	NT	50 (2)	40 (5)	67 (6)	33 (3)	25 (4)
	IPD	7	0 (6)	0 (1)	NT	33 (6)	50 (2)	NT	0 (5)	0 (2)	14 (7)	20 (5)	0 (2)
<i>Enterobacter spp.</i>	OPD	30	50 (20)	39 (18)	NT	64 (22)	56 (9)	NT	30 (23)	67 (3)	48 (25)	62 (21)	75 (4)
	IPD	5	0 (3)	25 (4)	NT	0 (3)	100 (1)	NT	0 (3)	NT	0 (3)	0 (4)	NT
<i>Acinetobacter baumannii</i>	OPD	1	0 (1)	0 (1)	IR	100 (1)	100 (1)	NT	NT	NT	NT	NT	0 (1)
	IPD	2	50 (2)	0 (1)	IR	50 (2)	0 (1)	NT	50 (2)	NT	0 (1)	100 (1)	NT
<i>Pseudomonas aeruginosa</i>	OPD	11	75 (8)	82 (11)	100 (5)	100 (4)	NT	100 (11)	50 (4)	NT	IR	100 (1)	IR
	IPD	6	33 (6)	20 (5)	0 (3)	40 (5)	NT	33 (6)	67 (3)	NT	IR	0 (1)	IR
<i>Proteus mirabilis</i>	OPD	1	NT	100 (1)	NT	NT	NT	NT	NT	NT	NT	0 (1)	NT
	IPD	3	50 (2)	50 (2)	NT	NT	50 (2)	NT	0 (2)	NT	0 (2)	100 (2)	NT
<i>Proteus vulgaris</i>	OPD	1	100 (1)	NT	NT	NT	100 (1)	NT	100 (1)	NT	100 (1)	NT	NT
	IPD	1	100 (1)	100 (1)	NT	NT	100 (1)	NT	100 (1)	NT	100 (1)	NT	NT
<i>Klebsiella oxytoca</i>	OPD	3	50 (2)	100 (1)	NT	100 (3)	100 (1)	NT	67 (3)	NT	67 (3)	100 (3)	NT
<i>Klebsiella pneumoniae</i>	OPD	9	40 (5)	50 (4)	NT	71 (7)	75 (4)	NT	33 (6)	100 (1)	25 (8)	83 (6)	100 (1)
	IPD	3	0 (2)	0 (2)	NT	0 (2)	0 (1)	NT	0 (3)	NT	0 (1)	33 (3)	NT
<i>Citrobacter koseri</i>	OPD	3	0 (1)	50 (2)	NT	100 (1)	67 (3)	NT	100 (1)	NT	50 (2)	NT	NT
<i>Citrobacter freundii</i>	OPD	1	100 (1)	NT	NT	NT	100 (1)	NT	100 (1)	NT	100 (1)	NT	NT
	IPD	3	0 (2)	100 (3)	NT	50 (2)	100 (3)	NT	0 (1)	NT	0 (1)	50 (2)	0 (1)

ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENS ISOLATED FROM DERMATOLOGY DEPARTMENT JAN – DEC 2025



**ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENS
ISOLATED FROM OBSTETRICS &
GYNAECOLOGY DEPARTMENT
(JAN – DEC 2025)**

Antimicrobial susceptibility for Gram-positive pathogens from the Obstetrics & Gynaecology department

[% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]

Gram Positive Cocci	Location	Isolate	Cefoxitin %(n)	Cotrimoxazole %(n)	Erythromycin %(n)	Linezolid %(n)	Tetracycline %(n)	Clindamycin %(n)	Chloramphenicol%(n)	Ciprofloxacin %(n)	Gentamicin %(n)	Norfloxacin %(n)	Nitrofurantoin %(n)	Ofloxacin %(n)	Doxycycline %(n)
<i>Staphylococcus aureus</i>	OPD	61	45 (61)	35 (17)	10 (20)	100 (31)	82 (17)	45 (20)	90 (20)	46 (11)	74 (39)	44 (27)	100 (35)	50 (2)	93 (14)
	IPD	97	36 (97)	44 (59)	9 (91)	100 (39)	65 (17)	46 (90)	91 (67)	50 (20)	76 (45)	0 (5)	100 (5)	33 (9)	100 (35)
<i>MSSA</i>	OPD	30	100 (30)	67 (6)	33 (6)	100 (18)	88 (8)	83 (6)	100 (6)	83 (6)	86 (21)	55 (20)	100 (21)	100 (1)	100 (1)
	IPD	37	100 (37)	46 (26)	11 (37)	100 (14)	75 (8)	53 (36)	97 (29)	83 (6)	86 (14)	NT	NT	33 (3)	100 (13)
<i>MRSA</i>	OPD	31	0 (31)	18 (11)	0 (14)	100 (13)	78 (9)	29 (14)	86 (14)	0 (5)	61 (18)	14 (7)	100 (14)	0 (1)	92 (13)
	IPD	60	0 (60)	42 (33)	7 (54)	100 (25)	56 (9)	41 (54)	87 (38)	36 (14)	71 (31)	0 (5)	100 (5)	33 (6)	100 (22)
<i>CONS</i>	OPD	2	50 (2)	NT	NT	100 (2)	NT	NT	NT	100 (1)	100 (1)	100 (2)	100 (2)	NT	NT
	IPD	5	20 (5)	0 (4)	0 (5)	100 (5)	0 (1)	0 (5)	40 (5)	NT	NT	NT	NT	NT	NT

Gram Positive Cocci	Location	Isolate	Erythromycin %(n)	Linezolid %(n)	Vancomycin %(n)	High Level Gentamicin %(n)	Ciprofloxacin %(n)	Teicoplanin %(n)	Norfloracin %(n)	Nitrofurantoin %(n)	Chloramphenicol %(n)	Doxycycline %(n)	Ampicillin %(n)
<i>Enterococcus faecalis</i>	OPD	41	0 (7)	100 (31)	98 (41)	69 (39)	14 (21)	90 (20)	18 (11)	85 (34)	80 (5)	100 (3)	67 (3)
	IPD	44	0 (9)	100 (29)	98 (42)	46 (41)	8 (26)	77 (17)	20 (15)	73 (26)	73 (11)	NT	100 (2)
<i>Enterococcus faecium</i>	OPD	36	0 (2)	100 (30)	100 (36)	82 (34)	18 (22)	95 (21)	80 (5)	91 (32)	50 (2)	0 (1)	0 (1)
	IPD	26	0 (10)	100 (13)	100 (18)	67 (24)	60 (5)	82 (17)	33 (6)	89 (9)	100 (11)	100 (2)	100 (2)
<i>Enterococcus spp.</i>	OPD	1	NT	100 (1)	100 (1)	100 (1)	0 (1)	NT	NT	100 (1)	NT	NT	NT
	IPD	2	NT	100 (2)	100 (1)	50 (2)	NT	100 (1)	0 (1)	100 (1)	NT	NT	NT



Antimicrobial susceptibility for Gram-negative pathogens from the Obstetrics & Gynaecology department

[% of susceptible (total number of isolates tested for a given antibiotic) =%(n)]

Gram-Negative Bacilli	location	Isolates	Amikacin%(n)	Gentamicin%(n)	Ceftriaxone%(n)	Piperacillin/tazobactam%(n)	Ceftazidime%(n)	Chloramphenicol%(n)	Ciprofloxacin%(n)	Imipenem%(n)	Ofloxacin%(n)	Ampicillin sulbactam%(n)	Tetracycline%(n)	Norfloxacin%(n)	Nitrofurantoin%(n)	Co-trimoxazole%(n)	Cefepime%(n)	Cefixime%(n)	Meropenem%(n)	Cefotaxime%(n)	Ampicillin%(n)	Amoxicillin Clavulanic acid%(n)	Colistin%(n)
<i>Enterobacter spp.</i>	OPD	217	47 (32)	70 (202)	37 (163)	65 (137)	0 (11)	NT	17 (30)	87 (167)	25 (4)	IR	33 (15)	50 (142)	70 (191)	55 (155)	17 (6)	21 (19)	75 (4)	24 (55)	IR	NT	100 (2)
	IPD	294	52 (138)	62 (178)	15 (220)	37 (195)	13 (105)	NT	20 (117)	60 (208)	35 (17)	IR	14 (14)	33 (99)	54 (153)	30 (128)	25 (20)	0 (3)	50 (4)	14 (51)	IR	NT	100 (10)
<i>Escherichia coli</i>	OPD	171	59 (66)	73 (155)	45 (92)	69 (98)	17 (6)	NT	19 (27)	96 (97)	33 (3)	NT	12 (17)	34 (100)	89 (157)	40 (95)	43 (7)	39 (13)	33 (3)	35 (80)	0 (3)	31 (67)	100 (2)
	IPD	181	62 (93)	73 (105)	18 (120)	59 (115)	21 (29)	87 (15)	17 (82)	87 (92)	33 (6)	60 (5)	18 (17)	38 (80)	82 (93)	38 (81)	22 (9)	14 (14)	70 (10)	17 (47)	13 (16)	30 (57)	100 (2)
<i>Klebsiella pneumoniae</i>	OPD	74	62 (13)	84 (67)	72 (50)	64 (56)	29 (7)	NT	17 (6)	90 (60)	100 (3)	0 (1)	75 (4)	100 (33)	26 (65)	76 (54)	75 (4)	100 (2)	NT	74 (19)	IR	43 (21)	100 (2)
	IPD	114	66 (71)	71 (51)	26 (84)	40 (78)	17 (47)	NT	20 (59)	78 (89)	80 (5)	NT	0 (3)	58 (25)	16 (43)	24 (42)	50 (8)	50 (2)	71 (7)	16 (19)	IR	13 (52)	100 (7)
<i>Klebsiella oxytoca</i>	OPD	19	75 (4)	77 (17)	64 (14)	50 (12)	0 (2)	NT	0 (2)	100 (14)	0 (1)	NT	0 (1)	71 (7)	50 (16)	50 (12)	0 (1)	0 (1)	NT	0 (5)	IR	33 (6)	NT
	IPD	15	40 (5)	75 (8)	25 (8)	63 (8)	0 (4)	NT	0 (4)	80 (10)	67 (3)	NT	NT	71 (7)	38 (8)	29 (7)	0 (3)	NT	100 (1)	0 (4)	IR	43 (7)	NT

Gram-Negative bacilli	Location	Isolates	Amikacin % (n)	Gentamicin % (n)	Ceftriaxone % (n)	Piperacillin/tazobactam	Ceftazidime % (n)	Ciprofloxacin % (n)	Imipenem % (n)	Tobramycin % (n)	Aztreonam % (n)	Norfloxacin % (n)	Nitrofurantoin % (n)	Co-trimoxazole % (n)	Tetracycline % (n)	Cefepime % (n)	Cefixime % (n)	Meropenem % (n)	Cefotaxime % (n)	Ampicillin Sulbactam % (n)	Ofloxacin % (n)	Netilmicin % (n)	Colistin % (n)
<i>Pseudomonas aeruginosa</i>	OPD	6	NT	NBP	IR	83 (6)	67 (6)	100 (3)	100 (5)	100 (6)	100 (3)	100 (3)	IR	IR	IR	NT	NBP	NT	IR	IR	NT	NT	NT
	IPD	14	0 (1)	NBP	IR	90 (10)	93 (14)	60 (5)	100 (7)	79 (14)	90 (10)	50 (2)	IR	IR	IR	100 (1)	NBP	100 (2)	IR	IR	0 (1)	100 (5)	NT
<i>Citrobacter freundii</i>	OPD	4	50 (2)	100 (1)	33 (3)	33 (3)	0 (1)	0 (2)	100 (2)	NT	NT	100 (2)	0 (2)	100 (2)	100 (1)	NT	NT	0 (1)	0 (1)	IR	NT	NT	NT
	IPD	9	50 (2)	50 (6)	40 (5)	83 (6)	50 (2)	0 (2)	100 (6)	NT	NT	50 (2)	40 (5)	60 (5)	NT	50 (2)	NT	NT	100 (2)	IR	50 (2)	NT	NT
<i>Citrobacter koseri</i>	OPD	25	78 (9)	65 (20)	35 (17)	85 (13)	50 (2)	33 (3)	100 (16)	NT	NT	50 (16)	86 (21)	73 (15)	50 (2)	NT	40 (5)	NT	56 (9)	NT	NT	NT	NT
	IPD	35	45 (11)	65 (26)	14 (22)	42 (24)	29 (7)	25 (12)	77 (26)	NT	NT	40 (15)	58 (19)	44 (16)	50 (2)	NT	NT	0 (2)	9 (11)	NT	NT	NT	NT
<i>Proteus mirabilis</i>	OPD	6	0 (2)	60 (5)	83 (6)	100 (3)	NT	NT	NT	NT	NT	100 (2)	IR	67 (3)	IR	100 (1)	NT	NT	NT	100 (1)	100 (1)	NT	IR
	IPD	7	0 (1)	50 (4)	50 (4)	50 (2)	50 (4)	33 (3)	NT	NT	NT	NT	IR	0 (1)	IR	67 (6)	NT	100 (4)	100 (1)	100 (2)	67 (6)	NT	IR
<i>Acinetobacter baumannii</i>	OPD	11	33 (3)	63 (8)	0 (4)	67 (6)	0 (3)	67 (3)	75 (8)	NT	IR	NBP	NBP	IR	NBP	0 (1)	NBP	NT	33 (3)	0 (1)	NBP	NT	NT
	IPD	116	12 (67)	18 (72)	9 (80)	4 (51)	0 (40)	12 (73)	5 (56)	NT	IR	NBP	NBP	IR	NBP	17 (24)	NBP	0 (9)	6 (18)	8 (38)	NBP	NT	100 (10)

Distribution of bacterial isolates from the Department of Obstetrics and Gynaecology


AST pattern of *Staphylococcus aureus* isolates from Obstetrics and Gynaecology department

AST pattern of *Enterobacter spp.* isolates from Obstetrics and Gynaecology department
